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2 Introduction 
  
2 Introduction   
 
2.1 Background and aim of the study 
The endothelium functions as the barrier between blood and tissue and thus 
regulates blood cell trafficking and plays an important role in vascular homeostasis 
(1). Therefore, the loss of proper endothelial function is associated with a number of 
pathological processes (2). The loss of proper endothelial function is related to an 
immense variety of diseases, including diabetes, hypertension, atherosclerosis, and 
other chronic inflammatory diseases. In acute and chronic inflammation, leukocyte-
endothelial cell interactions are early and critical events. 
An enormous issue is the repression of inflammation, therefore anti-inflammatory 
agents are extensively used clinically. However, anti-inflammatory compounds such 
as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and 
chemotherapeutic agents, are often characterized by limited efficacy and severe 
side-effects. Hence, there exists a great need for new targets and potent blockers of 
the inflammatory response (3). 
Flavopiridol, a synthetic flavonoid, is a pan-specific cyclin dependent kinase (Cdk) 
inhibitor. Flavopiridol was the first Cdk inhibitor to undergo clinical trials (4) and in a 
panel of 60 human cancer cell lines flavopiridol was proven to be a potent inhibitor of 
cell growth (5, 6). Currently, flavopiridol is tested as single agent as well as in 
combination with other agents in numerous clinical trials as drug against hematologic 
and solid cancers (http://www.clinicaltrials.gov). In the ongoing clinical trials against 
cancer, flavopiridol shows good compliance with limited toxicities at plasma 
concentrations up to 10-fold higher than those necessary to inhibit cell cycle 
progression in vitro (7).  
Recently, Cdk inhibitors were suggested to play relevant roles not only in cancer 
diseases but also in processes regarding immune response and inflammation. A few 
studies exist which suggest Cdk inhibitors as potential anti-inflammatory agents 
because of their ability to influence the apoptosis of neutrophils and therefore the 
resolution of inflammation (8, 9). It was reported, that flavopiridol was effective to 
inhibit synovial hyperplasia in collagen-induced arthritis in mice (10) and to suppress 
IL-6-inducible hepatic acute phase response proteins (11). Due to findings in cancer 
cell lines, where flavopiridol inhibited the activity of NF-B, a proinflammatory 
transcription factor, flavopiridol was suggested to might have an influence on 
inflammation (12).  
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Hitherto, no studies exist that focus on the impact of Cdk inhibitors in general and of 
flavopiridol in particular on the inflammation-activated endothelium. 
 
 
Thus, it was the aim of the present work  
 
1. to investigate the impact of flavopiridol on the interaction of leukocytes 
and the inflammation-activated endothelium in vivo and in vitro and 
 
2. to characterize the signaling mechanisms underlying the anti-
inflammatory actions of flavopiridol  
 
  
4 Introduction   
 
2.2 Inflammation 
Inflammation is part of the beneficial anti-microbial, immune defense system that has 
been honed and conserved by evolution over millions of years (13). Ideally, following 
prompt detection of a micro-organism by immune mechanisms, an inflammatory 
reaction should contain and destroy the organism before it multiplies, spreads, 
becomes established, or causes harm. Self-regulation and limitation are the key, final 
components of the response as the system must actively drive resolution of 
inflammation to restore tissue homeostasis (3). Nonresolution of inflammation can 
lead to atherosclerosis, obesity, cancer, chronic obstructive pulmonary disease, 
asthma, inflammatory bowel disease, or rheumatoid arthritis (14).  
 
Because of the importance of deleterious inflammatory responses in human disease, 
anti-inflammatory agents are extensively used clinically. Early anti-inflammatory 
agents were used long before their targets were known, such as non-steroidal anti-
inflammatory drugs (NSAIDs) as well as corticosteroids. More recently, successful 
anti-inflammatory agents were introduced whose targets were identified in advance, 
such as cytokines TNF or IL-1. However, anti-inflammatory agents have often 
limited efficacy and severe side-effects and, therefore, the extensive search for new 
anti-inflammatory agents possessing mechanisms of action different from those of 
marketed drugs holds on. 
2.2.1 The endothelium 
The endothelium is a thin monocellular layer that covers all the inner surface of the 
blood vessels with a surface area of approximately 350 m2. It separates the 
circulating blood from the tissues and is responsible for the exchange of materials 
between blood and tissues. Therefore, the endothelium is critically involved in vital 
functions of the cardiovascular system, including regulation of perfusion, fluid and 
solute exchange, homeostasis and coagulation, vasculogenesis, angiogenesis, and 
inflammatory responses. The endothelial lining of blood vessels in different organs 
differs with respect to morphology and permeability and is classified as 'continuous', 
'fenestrated', or 'discontinuous'. Furthermore, the release of mediators, antigen 
presentation, or stress responses of endothelial cells varies between species, 
different organs and vessel classes. Excessive or prolonged increases in 
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permeability of the endothelial monolayer, as in cases of chronic inflammation, may 
lead to tissue edema/swelling. The loss of proper endothelial function, or endothelial 
dysfunction, respectively is a hallmark for vascular diseases (13, 15). 
2.2.2 Leukocytes 
Leukocytes are derived from hematopoietic stem cells and are distinguished in two 
main types: granulocytes and agranulocytes ( Figure 2.1).  
 
Figure 2.1: Types of leukocytes. 
 
Granulocytes (polymorphonuclear leukocytes, PMNs) are eosinophils, basophils and 
neutrophils and are named for the numerous granules within their cytoplasm. Each of 
these granules contains a range of toxic products such as proteases, lysozyme, and 
lactoferrin (8). Basophils are responsible for allergic response (releasing histamine), 
while neutrophils and eosinophils are key players in the immune response against 
bacteria, fungi and parasites. They are attracted by and are believed to follow a 
concentration gradient of chemotactic stimuli released by invading pathogens or 
tissues under challenge. Neutrophils are recruited to the site of injury within minutes 
following trauma and are the hallmark of acute inflammation. 
Agranulocytes (mononuclear leukocytes) include lymphocytes, monocytes and 
macrophages. Lymphocytes are common in the lymphatic system. There are three 
types of lymphocytes: B cells, T cells, and natural killer (NK) cells. Monocytes are 
important for antibody response and once monocytes move from the bloodstream out 
leukocytes
agranulocytes
lymphocytes 
(20 - 25%)
T cell, B cell, 
NK cell
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(0.5 - 1%)
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into the body tissues, they differentiate allowing phagocytosis and become tissue 
macrophages.  
Leukocytes contribute to the inflammatory response by secreting cytotoxic and pro-
inflammatory compounds, by phagocytic activity, and by targeted attack on foreign 
agents. 
2.2.3 Leukocyte-endothelial cell interactions 
Interactions of leukocytes with endothelial cells are early events in immune 
surveillance of tissues, wound repair, and acute and chronic inflammation. 
Inflammatory responses in all tissue compartments require the emigration of 
leukocytes from the microvasculature through endothelial cells into the respective 
microenvironment (16). The leukocyte adhesion cascade to stimulated endothelial 
cells includes slow rolling, adhesion strengthening, intraluminal crawling, paracellular 
and transcellular migration, and migration through the basement membrane (Figure 
2.2).  
 
Figure 2.2: The leukocyte-endothelium adhesion cascade. 
The initial interaction of leukocytes with the endothelium lining the vessel wall is termed tethering, and 
the subsequent rotational movement along the vessel wall is termed rolling. These events are 
dependent on the family of the selectins and their counterreceptors. Chemokines trigger leukocytes to 
adhere and activate integrins to mediate binding to immunoglobulin superfamily members resulting in 
arrest. Adhesion strengthening and intravascular crawling are two steps which ultimately contribute to 
efficient emigration out of the vasculature. Numerous proteins, including JAMs, ICAM-1, and other 
molecules, have been implicated in the final step, the emigration process, including paracellular and 
transcellular transmigration. Key molecules involved are ICAM-1, intercellular adhesion molecule 1; 
JAM, junctional adhesion molecule; LFA-1, lymphocyte function-associated antigen 1; Mac-1, 
macrophage antigen 1, VCAM-1, vascular cell-adhesion molecule 1, VLA-4, very late antigen 4.      
The image is adapted from Ley et al. (17). 
 
Mac-1
ICAM-1Src kinases JAMs ICAM-1
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VLA-4
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signalling
LFA-1 – ICAM-1
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The first contact between neutrophils and the endothelium of postcapillary venules is 
known as capture or tethering and is mediated by selectins and their counter 
receptors (17, 18). Selectin binding and the presentation of chemokines by 
endothelial cells induce activation of signaling pathways in neutrophils that cause 
changes in integrin conformation (inside-out signaling). The endothelium has an 
active role in the rolling of leukocytes. Integrins participate in slow rolling and mediate 
arrest, e.g. slow rolling of neutrophils along the wall of inflamed venules is mediated 
by the 2-integrins, specifically LFA-1 and Mac-1 (19). In vitro and in vivo studies 
have established that leukocyte arrest during rolling is rapidly triggered by 
chemokines or other chemoattractants and is mediated by the binding of leukocyte 
integrins to immunoglobulin superfamily members, such as ICAM-1 and VCAM-1, 
expressed by endothelial cells (20, 21). The initial leukocyte-facilitated clustering of 
ICAM-1 requires Src-dependent phosphorylation of the actin-binding protein cortactin 
(22). Upon arrest, integrins bound to their ligands can signal into the neutrophil 
(outside-in signaling), stabilize the adhesion (postadhesion strengthening), activate 
different signaling pathways, and initiate transmigration. Transmigration through 
venular walls is the final step in the process of leukocyte emigration into inflamed 
tissues and can occur with minimal disruption to the complex structure of vessel 
walls. Some endothelial junctional molecules actively mediate leukocyte 
transendothelial migration, such as ICAM-1 and JAMs.  
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2.2.4 The selectin family 
The selectin family of cell adhesion molecules (CAMs) consists of three members 
which all mediate rolling of leukocytes along the endothelium (23). P-selectin is 
stored in granules in endothelial cells and platelets and translocates rapidly to the cell 
surface in response to several inflammatory stimuli. E-selectin is present exclusively 
in endothelial cells and its expression is regulated by increased transcription after 
stimulation by inflammatory cytokines such as TNF and IL-1. The third selectin 
molecule L-selectin is expressed on many subclasses of leukocytes and is rapidly 
discarded from the surface of the leukocyte after activation (24). 
2.2.5 Integrins and the immunoglobulin (Ig) superfamily of CAMs 
Integrins are expressed constitutively on leukocytes and many other cell types. 
Integrins are activated rapidly from a low-affinity to a high-affinity state following cell 
activation and ligand binding. Integrins mediate adhesion of cells to matrix proteins, 
cellular counterreceptors and many other substrates (25, 26). The interaction 
between integrins and CAMs of the Ig superfamily is particularly important in 
inflammation. The Ig superfamily of CAMs consists of large proteins that are 
expressed on many different cell types, including endothelial cells where the 
expression of some of these molecules is upregulated by inflammatory cytokines. In 
leukocyte recruitment, interactions between 2 integrins on the surface of leukocytes 
and ICAM-1 on endothelial cells are important mechanisms in leukocyte firm arrest 
on the endothelium and their transendothelial migration to sites of inflammation as 
well as their function as costimulatory molecules for T cell activation. 
2.2.6 Regulation of VCAM-1 and ICAM-1 
Intercellular adhesion molecule-1 (ICAM-1, CD54) and vascular cell adhesion 
molecule-1 (VCAM-1, CD106) are inducible cell adhesion glycoproteins of the 
immunoglobulin supergene family. VCAM-1 is not constitutively expressed in most 
tissues but is upregulated through de novo synthesis after stimulation with TNF and 
IL-1. ICAM-1 and VCAM-1 are involved in firm adhesion of leukocytes to the apical 
surface of endothelial cells through interactions with leukocyte CD11a/CD18 (LFA-1) 
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and/or CD11b/CD18 (Mac-1) and CD49a/CD29, respectively (22). VCAM-1 clustering 
has been observed in the steps leading to transmigration.  
 
ICAM-1 is constitutively expressed on the cell surface and is overexpressed by 
proinflammatory mediators in a wide variety of cell types, including fibroblasts, 
leukocytes, endothelial cells, and epithelial cells (27). These stimuli increase ICAM-1 
expression primarily through activation of ICAM-1 gene transcription. The 
architecture of the ICAM-1 promoter is complex (Figure 2.3), containing a large 
number of binding sites for inducible transcription factors, the most important of which 
is NF-B. NF-B acts in concert with other transcription factors or transcriptional 
coactivators which facilitate the assembly of distinct stereospecific transcription 
complexes on the ICAM-1 promoter. These transcription complexes presumably 
mediate the induction of ICAM-1 expression in different cell types and in response to 
different stimuli (28).  
 
Figure 2.3: Schematic structure of the ICAM-1 promoter.  
The ICAM-1 promoter contains a number of binding sites for inducible transcription factors (including 
NF-B, AP-1, Ets-1, C/EBP, Sp-1), that mediate various activation signals elicited at the cell surface. 
Upstream of each initiation site is a consensus TATA element that binds the general transcription 
factor IID (TFIID). The C/EBP site cooperates with the neighboring NF-B site to mediate the TNF 
and IL-1 induction of ICAM-1. The IFN- response is mediated by STAT binding to the IFN- 
response element (IRE).  
2.2.7 The nuclear factor-kappa B (NF-B) transcription factor 
The nuclear factor-kappa B (NF-B) transcription factor plays a critical role in diverse 
cellular processes associated with proliferation, apoptosis, inflammation, as well as 
innate and adaptive immune responses (29, 30). This pleiotropic transcription factor 
can be activated by a diverse spectrum of modulating stimuli, linking NF-B with an 
ever-increasing array of genetic targets (31). 
The NF-B family of transcription factors consists of five members, p50, p52, p65 
(RelA), c-Rel, and RelB. NF-B dimers bind to B sites within the 
promoters/enhancers of target genes and regulate transcription through the 
AP-1 NF-B NF-BC/EBP
ICAM-1
TATA
TNF
STAT Sp1
IL-1
TFIIDEts-1
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recruitment of coactivators and corepressors. In untreated cells NF-B belongs to its 
inactive state where NF-B dimers are associated with one of three typical IB 
proteins, IB, IB, or IB, or the precursor proteins p100 and p105. These IBs 
maintain NF-B dimers in the cytoplasm and are crucial for signal responsiveness. 
By contrast, in human cancers and leukemias NF-B is often constitutively activated 
(32). 
2.2.8 The NF-B signaling pathway  
NF-B is controlled by distinct regulatory pathways, the canonical, noncanonical and 
atypical pathways. The most frequently observed is the canonical, or classical 
pathway, which is induced in response to various inflammatory stimuli (Figure 2.4), 
the other pathways are induced by RNA virus infection or lymphokines.  
In the canonical pathway, the IKKs, which form a complex composed of two catalytic 
subunits, IKK and IKK, and a regulatory subunit, IKK/NEMO, are responsible for 
activation of the NF-B transcription factor (33). Inducing stimuli trigger IKK activation 
by phosphorylating IKK/. Activated IKK leads to phosphorylation, ubiquitylation, 
and degradation of IB. IB is rapidly degraded through the 26S proteasome, 
thereby freeing multiple NF-B dimers, although the p65:p50 heterodimer is likely the 
primary target of IB. Phosphorylation of p65 on a number of Ser residues is 
required for transcriptional activation; Ser276 and Ser536 are thought to be the most 
important phosphorylation sites in regulating transcriptional activity. Inducible 
phosphorylation of p65 at Ser276 by protein kinase A (PKA) has been demonstrated 
to be crucial for NF-B transcriptional activity downstream of IB degradation (34) 
and promotes the interaction of p65 with the transcriptional coactivators CBP (CREB-
binding protein) and p300 (35). Released NF-B dimers are further activated through 
various posttranslational modifications and translocate to the nucleus where they 
bind to specific DNA sequences and promote transcription of target genes (36).  
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Figure 2.4: Relevant regulatory steps in the canonical NF-B pathway. 
The canonical NF-B pathway is induced by inflammatory stimuli, such as TNF, and is dependent on 
activation of IKK. This activation results in the phosphorylation (P) of IB at Ser32 and Ser36, 
leading to its ubiquitylation (Ub) and subsequent degradation. Released NF-B dimers translocate to 
the nucleus and bind B sites in the promoters or enhancers of target genes, which leads to their 
transcription. 
 
  
IKK IKK
NEMO
Inflammatory stimuli
p65
IB
p50
P
IB
Ub
Ub
Ub
Proteasomal
degradation
Cytoplasm
Nucleus
p65p50
p65p50
B site
P
Survival, 
proliferation, 
inflammation,
immune regulation
Kinases,
acetylases,
phosphatases
Ac
P
12 Introduction   
 
2.3 Cyclin dependent kinases 
The cyclin dependent kinases (Cdks) are serine/threonine kinases and part of the 
diverse protein kinase family. They are essential facilitators of life at the molecular 
level via their ubiquitous phosphorylation reactions (37). The majority of Cdks 
identified rely on binding partners called cyclins for their activation. In all, there are 13 
Cdks and 25 identified cyclins known so far and although there is a high level of 
sequence and structural homology between them, Cdks can be classified in two 
groups based on their roles in cell cycle, including Cdk1, Cdk2, Cdk3, Cdk4, Cdk6, 
and Cdk7 and those responsible for transcriptional regulation, including Cdk5, Cdk7, 
Cdk8, Cdk9, Cdk10, Cdk11, Cdk12, and Cdk13 (38, 39). 
2.3.1 Cell cycle Cdks 
The Cdks have been traditionally described as key regulators of the cell cycle, 
whereby different Cdks become activated during cell-cycle progression when 
complexed with their associated cyclin partners (39). Three interphase Cdks (Cdk2, 
Cdk4, and Cdk6), a mitotic Cdk (Cdk1), and ten cyclins that belong to four different 
classes (the A-, B-, D- and E-type cyclins) regulate the cell cycle (Figure 2.5).  
 
 
Figure 2.5: The stages of the cell cycle and the regulatory Cdk/cyclin complexes. 
The transition from one cell cycle phase to another is regulated by different cellular proteins. Key 
regulatory proteins are the Cdks, which become activated at specific points of the cell cycle. Cdk4 and 
Cdk6 associated with cyclin D together with Cdk2 associated with cyclin E control G1 phase 
progression as well as G1/S transition. In early S phase, Cdk2/cyclin A complexes promote DNA 
replication and cell cycle progression, whereas cyclin A and cyclin B in complexes with Cdk1 control 
the G2/M transition. Cdk1 complexed with cyclin B drives cell division.  
S G2
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G1Cdk6
cyclin D
Cdk4
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Apart from the binding to proper cyclin, Cdks undergo an activating phosphorylation 
by Cdk7/cyclin H also named CAK, Cdk-activating kinase (Figure 2.6). CAK itself is a 
trimeric complex consisting of the catalytic component Cdk7, a regulatory subunit 
cyclin H, and a RING finger assembly factor called ménage a trois (MAT1) (40, 41). 
 
 
Figure 2.6: Function of CAK, Cdk activating kinase. 
Activation of human Cdks is a multistep process. It starts with binding to cyclins, followed by specific 
phosphorylation (P) within the activation loop (T-loop) by Cdk7/cyclin H (CAK), which leads to 
uncovering of the active site. The image is adapted from Wesiersky and Gadek (42). 
2.3.2 Transcriptional Cdks 
Only a certain subset of Cdk-cyclin complexes is directly involved in driving the cell 
cycle. Cdk7 complexed with cyclin H provides a direct link between regulation of cell 
cycle and transcription because it is both CAK and a constituent of the basal 
transcription factor TFIIH. Transcriptional kinases, such as Cdk8 with cyclin C and 
Cdk9 with cyclin T, constitute a second nonoverlapping group of Cdks. The 
transcriptional Cdks promote initiation and elongation of nascent RNA transcripts by 
phosphorylation of the largest subunit of RNA polymerase II (Pol II) (42, 43). RNA Pol 
II is subjected to a tight control at various steps during the transcription cycle, 
including the recruitment of transcription preinitiation complex (PIC) to DNA, 
transcription initiation, promoter clearance, promoter-proximal pausing, elongation, 
termination, and re-initiation (44). In the process of gene activation, RNA Pol II is 
phosphorylated by the preinitiation complex subunit TFIIH at Ser5 within the carboxy 
terminal domain (CTD) coinciding with transcription initiation and promoter clearance 
(40, 45). Cdk9 is one of the major CTD kinases that phosphorylates RNA Pol II at 
Ser2 and signifies productive transcription elongation (Figure 2.7). Moreover, Cdk9 
does not only phosphorylate CTD of RNA Pol II but also other proteins bound to the 
transcriptional complex. For example, the negative elongation factors NELF (negative 
elongation factor) and DRB-sensitivity inducing factor (DSIF), which repress 
transcriptional elongation, are phosphorylated and thus inactivated by Cdk9 (43). 
 
Cdk7/cyclin H
(CAK)
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Figure 2.7: Phosphorylation of the C-terminal domain of the RNA polymerase II. 
The C-terminal domain of the RNA polymerase II is hypophosphorylated when initially recruited to 
genes, and undergoes sequential phosphorylation at Ser5 by Cdk7/cyclin H and at Ser2 at  
Cdk9/cyclin T at the start of elongation. The image is adapted from Wesiersky and Gadek (42). 
 
2.4 The Cdk9-cyclin T1 complex 
Cdk9 associates with each of four cyclins (T1, T2a, T2b and K), forming distinct 
positive transcription elongation factors (P-TEFb). The majority of Cdk9 is complexed 
with cyclin T1 in nuclear speckles and a small fraction of Cdk9 is found in an 
apparently uncomplexed form in the cytoplasm. Studies have shown that nuclear     
P-TEFb exists in two functionally distinct complexes. Half of nuclear P-TEFb is found 
as an inactive complex associated with HEXIM1 and 7SK snRNA (46). 
Transcriptionally active P-TEFb associates with the bromodomain containing protein, 
Brd4 (Figure 2.8) (47).  
 
Figure 2.8: Nuclear states of P-TEFb in the resting cell.  
Approximately half of nuclear P-TEFb is in inactive state associated with HEXIM1 and 7SK snRNA. 
The component that is actively involved in RNA Pol II dependent transcription is associated with Brd4. 
  
HEXIM/7SKRNAcyclin T1 Brd4
Cdk9
P-TEFb
inactive active
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2.4.1 Function of the P-TEFb complex 
The P-TEFb complex is widely implicated in the control of basal gene expression, 
where it is involved in transitioning paused RNA Pol II to enter productive 
transcriptional elongation mode by phosphorylating Ser2 in the CTD of the RNA Pol II 
(Figure 2.7) (48). Moreover, P-TEFb integrates mRNA synthesis with histone 
modification, pre-mRNA processing, and mRNA export (49). P-TEFb function relies 
on Cdk9 protein kinase activity (50). RNA Pol II transcriptional regulation is an 
essential process for guiding eukaryotic gene expression. In complex organisms, 
elongation control is critical for the regulated expression of most genes. In those 
organisms, the function of P-TEFb is influenced negatively by HEXIM proteins and 
7SK snRNA and positively by a variety of recruiting factors (51). P-TEFb is required 
for transcription of most genes, including heat shock and c-Myc genes and also 
promotes efficient transcription of the full-length HIV genome (52). 
P-TEFb plays a key role in cellular activation, proliferation, and differentiation. Thus, it 
inherits a central role in normal and disease states. P-TEFb has recently been shown 
to be involved in cancers, AIDS, cardiac hypertrophy, and inflammation (53, 54). 
 
Figure 2.9: Role of P-TEFb in various diseases. 
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2.5 Cyclin dependent kinase inhibitors  
The activity of Cdk-cyclin complexes is regulated by the phosphorylation of Cdks, and 
also by the association with the members of two endogenous inhibitor families (CKIs) 
(55, 56). The INK4 (inhibitor of Cdk4) family includes p16INK4a, p15INK4b, p18INK4c, and 
p19INK4d, which bind to and inhibit Cdk4 and Cdk6. The Cip/Kip families include 
p21CIP1, p27KIP1 and p57KIP2, which bind to all the Cdk-cyclin complexes and inhibit 
their activities (57). In malignant cells, altered expression of Cdks and their 
modulators, including overexpression of cyclins and loss of expression of Cdk 
inhibitors, results in deregulated Cdk activity, providing a selective growth advantage 
(58). Cell cycle deregulation is one of the first steps that transform normal cells into 
tumor cells. For this reason, targeting Cdks by specific inhibitors may slow growth or 
induce apoptosis. Because of their critical role in cell cycle progression and cellular 
transcription, as well as the association of their activities with apoptotic pathways, the 
Cdks comprise an attractive set of targets for novel anticancer drug development. 
The first generation of Cdk-cyclin inhibitors are low-molecular weight molecules, 
composed as ATP-competitive inhibitors, such as flavopiridol and roscovitine, which 
are currently involved in a large number of clinical trials (59). Further, the 
development of ATP-noncompetitive Cdk-cyclin inhibitors has been launched. 
2.5.1 Flavopiridol (Alvocidib) 
Flavopiridol (Alvocidib) is a currently synthetical produced flavonoid, although its 
chemical structure is identical to a product obtained from the stem bark of Dysoxylum 
binectariferum, a plant used in India as herbal medicine (60).  
 
Figure 2.10: Structure of flavopiridol. 
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Flavopiridol has been found to have strong activity against multiple Cdks. In addition, 
flavopiridol is active to a lesser degree on tyrosine kinases, such as the epidermal 
growth factor receptor (EGFR) and protein kinase C (PKC) (Table 2.1) (6). 
Flavopiridol has a high potency to inhibit the proliferation of a broad range of human 
tumor cell lines after prolonged exposure time and inhibits in vivo the growth of 
human tumors, such as leukemias and lymphomas (61). Flavopiridol is also proposed 
as potential antiviral drug because it blocks HIV-1 replication. 
Interestingly, flavopiridol interferes with the cell cycle at two points, it arrests the cell 
cycle at the G2/M phase and delays the G1 to S phase progression (6). Structure-
activity studies have shown that flavopiridol interferes with binding of ATP to the 
adenine-binding pocket of Cdks, such as Cdk2 (62). Flavopiridol modulates 
transcriptional processes by the potent inhibition of P-TEFb, resulting in suppressed 
transcription and decreased phosphorylation of RNA Pol II (63). The transcripts that 
are most sensitive to Cdk9 inhibition are those with short half-lifes because their 
levels decrease when initiation and elongation of transcription are inhibited. Thus, 
this transcriptional inhibition leads to a decrease in levels of proteins, such as cyclin 
D1, VEGF and Mcl-1 essential for cell cycling and survival (64, 65).  
 
Table 2.1: Activity of flavopiridol on cellular kinases. 
 
Family Kinase IC50 (µM) 
EGFR family EGFR 21-25 
Signal transducing kinases PKA 122-145 
 PKC 6 
Cyclin dependent kinases Cdk1/cyclin B 0.03-0.4 
(direct inhibition) Cdk2/cyclin A 0.1 
 Cdk2/cyclin E 0.1 
 Cdk4/cyclin D 0.02-0.04 
 Cdk6/cyclin D 0.06 
 Cdk7/cyclin H 0.11-0.3 
 Cdk9/cyclin T 0.003 
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2.5.2 Flavopiridol in clinical trials 
In preclinical studies, flavopiridol was active in diverse hematopoietic cell lines (66, 
67) and induced G1 and G2/M arrest in many exponentially growing tumor cell types. 
Flavopiridol was the first Cdk inhibitor to enter clinical trials and is currently in clinical 
trials for the treatment of different cancers (phase I/II) (68, 69).  
Clinical tumor responses could be observed on different types of progressive tumors 
refractory to conventional treatment, such as non-Hodgkin’s lymphoma, human 
neoplasms and renal, colon, and prostate cancers. The beneficial effects with 
flavopiridol were based on the inhibition of Cdks to prevent and/or treat abnormalities 
in the cell cycle and concentrations between 300 and 500 nM were achieved safely 
(4). Especially in poor-risk acute myelogenous leukemia (AML) and in chronic 
lymphocytic leukemia (CLL) some encouraging responses were noted with 
flavopiridol as single agent or in combinations with chemotherapy (70, 71). Recent 
findings revealed that binding to human plasma proteins reduces free flavopiridol 
concentration and makes continuous intravenous infusion dosing ineffective. 
However, flavopiridol, when administered by a 30-min intravenous bolus followed by 
a 4-hour continuous intravenous infusion, is effective in high-risk, refractory chronic 
lymphocytic leukemia (72). A recently developed liposomal formulation of the drug 
ought to increase the drug’s half-life and perhaps its efficacy (73). 
2.6 Cdk inhibitors as anti-inflammatory approach 
The Cdk inhibitors play an integral role in the regulation of the cell cycle and 
transcriptional regulation and have also been suggested as potential anti-
inflammatory agents that can influence the resolution of inflammation (8).  
Apoptosis of inflammatory cells and their subsequent clearance by macrophages are 
key mechanisms in successful resolution of inflammation. Cdk inhibitors have been 
used for the selective induction of apoptosis in actively proliferating cancer cell lines 
for several years (74). The induction of apoptosis by Cdk inhibitors seems to be 
mediated by the modulation of Bcl-2 family members and to be executed in a 
caspase-dependent manner (75). A panel of Cdk inhibitor drugs have been shown to 
promote neutrophil apoptosis in a concentration- and time-dependent manner. 
Apoptosis of neutrophils ensures that toxic neutrophil granule contents are securely 
packaged in apoptotic bodies and expedites phagocytosis occurs by macrophages. 
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Effects on other cell types including lymphocytes and fibroblasts have also been 
demonstrated with Cdk inhibitor drugs indicating that they may have pleiotropic anti-
inflammatory, pro-resolution activity (8). Cdk inhibitor drugs have been reported to be 
efficacious in resolving established animal models of neutrophil-dominant and 
lymphocyte-driven inflammation. Neutrophils have functional Cdks, are 
transcriptionally active and demonstrate augmented apoptosis in response to Cdk 
inhibitor drugs, while lymphocyte proliferation and secretory function are inhibited. 
Recently, it was reported, that specific inhibitors of Cdks facilitate resolution of 
inflammation by augmenting neutrophil apoptosis (9).  
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3 Materials and Methods 
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3.1 Materials 
3.1.1 Flavopiridol 
Flavopiridol was provided from the National Cancer Institute. Flavopiridol was 
solubilized in DMSO at 10 mM and stored at -20°C. For experiments, flavopiridol was 
freshly diluted in growth medium to 10 µM and further diluted to the indicated 
concentrations. 
3.1.2 Biochemicals, inhibitors, dyes, and cell culture reagents 
Reagent Producer 
Accustain®  formaldehyde Sigma-Aldrich, Taufkirchen, Germany 
Amphotericin B PAA Laboratories, Pasching, Austria 
BC Assay reagent Interdim, Montulocon, France 
Bradford ReagentTM Bio-Rad, Munich, Germany 
Calyculin Millipore, Schwabach/Ts., Germany 
CellTiter BlueTM Promega, Madison, WI, USA 
Collagen A/G Biochrome AG, Berlin, Germany 
Collagenase G Biochrome AG, Berlin, Germany 
Complete® Roche diagnostics, Penzberg, Germany 
Dianisidine-hydrochlorid Sigma-Aldrich, Taufkirchen, Germany 
Dihydrorhodamine-123 (DHR) Invitrogen, Karlsruhe, Germany 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
Endothelial Cell Growth Medium (ECGM) Provitro, Berlin, Germany 
FCS gold PAA Laboratories, Pasching, Austria 
fMLP Sigma-Aldrich, Taufkirchen, Germany 
Formaldehyde, 16% ultrapure Polysciences Europe GmbH, Eppelheim, 
Germany 
M199 Medium PAA Laboratories, Pasching, Austria 
Myristoylated PKCθ pseudosubstrate 
inhibitor 
Calbiochem, Darmstadt, Germany 
NaF  Merck, Darmstadt, Germany 
Na3VO4  ICN Biomedicals, Aurora, Ohio, USA 
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Reagent Producer 
Page RulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin PAA Laboratories, Pasching, Austria 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
PermaFluor mounting medium Beckman Coulter, Krefeld, Germany 
PMSF  Sigma-Aldrich, Munich, Germany 
RNAlater Ambion, Austin, TX, USA 
SP600125 Enzo Life Sciences, Lörrach, Germany 
Streptomycin PAA Laboratories, Pasching, Austria 
TBB Tocris Bioscience, Bristol, UK 
Tumor necrosis factor (TNF)- PeproTech GmbH, Hamburg, Germany 
Triton X-100 Merck, Darmstadt, Germany 
 
 
PBS (pH 7.4) PBS+ Ca2+/Mg2+ (pH 7.4) 
NaCl  132.2 mM NaCl  137 mM 
Na2HPO4  10.4 mM KCl 2.68 mM 
KH2PO4  3.2 mM Na2HPO4  8.10 mM 
H2O  KH2PO4  1.47 mM 
  MgCl2  0.25 mM 
  CaCl2  0.50 mM 
  H2O   
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3.1.3 Technical equipment 
Name Device Producer 
AB7300 RT-PCR Real-time PCR system Applied Biosystems, 
Foster City, CA, USA 
Axioskop Upright microscope Zeiss, Jena, Germany 
Culture flasks, plates, 
dishes 
Disposable cell culture 
material 
TPP, Trasadigen, 
Switzerland 
Curix 60 Tabletop film processor Agfa, Cologne, Germany 
Cyclone Storage Phosphor Screens Canberra-Packard, 
Schwadorf, Austria 
FACSCalibur Flow cytometer Becton Dickinson, 
Heidelberg, Germany 
ibidi slides  Microscope slide ibidi GmbH, Munich, 
Germany 
LSM 510 Meta 
 
Confocal laser scanning 
microscope 
Zeiss, Jena, Germany 
Mikro 22R Table centrifuge Hettich, Tuttlingen, Germany 
Nanodrop® ND-1000 Spectrophotometer Peqlab, Wilmington, DE, 
USA 
Nucleofector II Electroporation device Lonza GmbH, Cologne, 
Germany 
Odyssey 2.1 Infrared Imaging System  LI-COR Biosciences, 
Lincoln, NE, USA 
Orion II Microplate 
Luminometer 
Luminescence Berthold Detection Systems, 
Pforzheim, Germany 
Polytron PT1200 Ultrax homogenizer Kinematica AG, Lucerne, 
Switzerland 
SpectraFluor PlusTM Microplate multifunction 
reader 
Tecan, Männedorf, Austria 
SunriseTM Microplate absorbance 
reader 
Tecan, Männedorf, Austria 
Vi-Cell™ XR Cell viability analyzer Beckman Coulter, Fullerton, 
CA, USA 
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3.2 Cell culture 
3.2.1 Isolation and cultivation of human umbilical vein endothelial cells 
Human umbilical cords were kindly provided by Klinikum München Pasing, 
Frauenklinik Dr. Wilhelm Krüsmann, and Rotkreuzklinikum München. Primary human 
umbilical vein endothelial cells (HUVECs) were isolated by collagenase treatment of 
umbilical cords (76). Experiments were performed using cells at passage 3. Cells 
were cultivated on 0.001% collagen G-coated flasks, plates, or dishes in growth 
medium. For splitting and seeding (1:3), cells were washed twice with pre-warmed 
PBS before incubation with T/E for 1-2 minutes at 37°C. The digest was terminated 
by adding approximately 20 ml stopping medium. Next, cells were centrifuged for 5 
minutes at 1,000 rpm to remove the T/E. The pellet was resuspended in pre-warmed 
growth medium and cells were plated. 
 
Growth medium  Stopping medium 
ECGM 500 mL  M199 500 mL 
Supplement 23.5 mL  FCS 50 mL 
FCS 50 mL    
Antibiotics 3.5 mL    
 
Trypsin/EDTA (T/E) 
Trypsin  0.05% 
EDTA  0.20% 
PBS   
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3.2.2 Isolation and cultivation of neutrophils 
Human neutrophil granulocytes were separated from heparinized peripheral blood of 
healthy volunteers. CD15 MicroBeads (Mini-Macs, Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) were added to the whole blood for 30 minutes at 4°C, which 
labeled the neutrophils magnetically. Using whole blood columns, CD15+ cells were 
directly separated from whole blood and collected in neutrophil isolation medium. 
Cells were counted and kept at room temperature in HEPES buffer or neutrophil 
growth medium until use (usually < 30 min). Assays using neutrophils were 
performed at 37°C. 
 
HEPES buffer (pH 7.4) 
NaCl 125 mM 
KCl 3 mM 
NaH2PO4 1.25 mM 
CaCl2 2.5 mM 
MgCl2 1.5 mM 
Glucose 10 mM 
Hepes 10 mM 
H2O  
 
 
 
 
 
 
  
 
 
 
  
Neutrophil isolation medium 
PBS 500 mL 
BSA 2.5 mL 
EDTA 2 mM 
Neutrophil growth medium 
M199 500 mL 
FCS 10 mL 
Antibiotics 3.5 mL 
26 Materials and Methods   
 
3.3 Cytotoxicity assays 
3.3.1 CellTiter-Blue™ cell viability assay 
Cell viability in HUVECs was analyzed via measuring the reduction of resazurin to 
resorufin (CellTiter-Blue™). 2.5 x 104 cells/well were seeded into 96-well plates and 
treated with flavopiridol for 24 and 48 hours. Resazurin was added to the medium 
and after two hours of incubation the conversion of resazurin to resorufin was 
determined. The assay was performed as described in the provided protocol of 
CellTiter-BlueTM Cell Viability Assay. The reduction of resazurin was determined by 
calculating the ratio of fluorescence at 530/590 nm in a SpectraFluor Plus plate 
reader. 
 
 
Figure 3.1: CellTiter-Blue™ cell viability assay.  
Conversion of resazurin to resorufin by metabolically active cells. The image is adapted from 
www.promega.com. 
3.3.2 Quantification of DNA fragmentation by PI staining (Nicoletti method)  
During the apoptotic process endogenous endonucleases become activated and 
cause the fragmentation of nuclear DNA into oligonucleosomal-size fragments. A 
widely used assay to quantify apoptotic cell death is the counting of nuclei with 
subdiploid DNA content after staining with propidium iodide (PI). Quantification of 
apoptosis was carried out according to Nicoletti et al (77). Cells were permeabilized 
in a buffer containing PI and fluorescence was measured by flow cytometry. The 
whole DNA content of cells is stained independently from their viability or membrane 
integrity. Most cells of normal untreated cell populations are in G0/G1 phase with 
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diploid DNA content and emit a homogenous fluorescence after binding of PI to DNA. 
DNA fragments of apoptotic cells or apoptotic bodies respectively have a lower 
fluorescence and thus appear “left” to the G0/G1 peak in the FL2 histogram. 
Confluent HUVECs were treated for 24 and 48 hours with increasing concentrations 
of flavopiridol. After stimulation, cell culture supernatants containing apoptotic cells 
were collected. Cells were washed, trypsinized, resuspended in the supernatant, and 
centrifuged 10 minutes at 600 x g at 4°C. After another washing step with PBS, cells 
were resuspended in a buffer (0.1% sodium citrate and 0.1% Triton X-100 in PBS) 
containing 2 mg/ml PI and incubated protected from light overnight at 4°C. The 
fluorescence intensity of PI was measured in the logarithmic mode of the 
fluorescence channel 2 (FL2, λem 585 nm) using a flow cytometer. Nuclei left to the 
G1 peak containing hypodiploid DNA were considered as apoptotic. 
 
FACS buffer (pH 7.37)  
NaCl 8.12 g 
KH2PO4 0.26 g 
Na2HPO4 2.35 g 
KCl 0.28 g 
Na2EDTA 0.36 g 
LiCl 0.43 g 
NaN3 0.20 g 
H2O ad 1.0 L 
 
   
Figure 3.2: Determination of DNA fragmentation by PI staining (Nicoletti method). 
Representative examples of apoptotic analysis of either control cells (left panel) or 500 nM flavopiridol-
treated cells (right panel) are displayed. Sub-G0/G1 peaks are considered as apoptotic cells. 
apoptotic cells
G0/G1
G2/M
S
sub-G0/G1
untreated cells
apoptotic cells
flavopiridol-treated cells
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3.4 Concanavalin A-induced liver injury model 
The concanavalin A-induced liver injury model was performed in collaboration with 
PD Dr. Gabriele Sass and Prof. Dr. Gisa Tiegs from the Division of Experimental 
Immunology and Hepatology of the University Medical Center Hamburg-Eppendorf, 
Hamburg, Germany. 
3.4.1 Procedures 
Male C57Bl/6 mice (6-8 weeks; weight range: 18-22 g) were obtained from the 
animal facilities of the University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany. Concanavalin A (ConA; dissolved in pyrogen-free saline) was purchased 
from Sigma-Aldrich (Taufkirchen, Germany). It was administered to mice 
intravenously at 15 mg/kg. Flavopiridol (44 ng in 250 µl PBS; bolus sufficient to reach 
100 nM plasma concentration) was administered intravenously 15 minutes prior to 
ConA administration. Mice were sacrificed eight hours after ConA application. 
Liver damage was assessed by measuring plasma enzyme activity of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) (78), using an 
automated procedure with the COBAS MIRA® (Roche, Basel, Suisse).  
3.4.2 Hematoxylin and eosin (H&E) staining 
Liver tissue was fixed in 4% phosphate-buffered formaldehyde and embedded into 
paraffin. Paraffin sections of 3 µm were cut and stored at room temperature until use. 
Routine histology [hematoxylin and eosin (H&E) staining] was performed in order to 
evaluate basic histomorphological features. 
3.4.3 Granulocyte staining 
Paraffin sections of 5 µm were cut and stained for chloroacetate esterase, an 
enzyme usually considered specific for cells of granulocytic lineage. A naphthol AS-D 
chloroacetate esterase kit (Sigma-Aldrich) was used according to the manufacturer’s 
protocol and the intensity of staining was evaluated by microscope. 
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3.4.4 Myeloperoxidase (MPO) activity  
Myeloperoxidase (MPO) activity in the tissue and the number of present neutrophils 
are directly proportional (79). Therefore, to measure the accumulation of neutrophils 
in liver tissue, the activity of MPO is determined. Liver tissues, 80 mg each, were 
crushed and homogenized on ice in phosphate buffer (pH 6.0) containing 1% of 
hexadecyltrimethyl ammonium bromide (HTAB). After lysis by sonication, the 
suspension was centrifuged for 30 minutes at 12,000 rpm at 4°C. MPO activity of the 
supernatants was determined by agitating equal volumes of the supernatants and the 
substrate solution [0.06% dianisidine and 0.0009% H2O2 in phosphate buffer (pH 
6.0)]. MPO activity was measured by determination of the absorbance at 540 nm with 
a SpectraFluor Plus plate reader.  
 
Phosphate buffer (pH 6.0)  
KH2PO4 9.08 g/L 
Na2HPO4 11.88 g/L 
H2O  
3.5 Cremaster muscle preparation and intravital microscopy  
The open cremaster muscle preparation and intravital microscopy was performed in 
collaboration with Dr. Alexander Khandoga and Prof. Dr. Fritz Krombach from the 
Walter Brendel Center of Experimental Medicine, Munich, Germany. 
3.5.1 Surgical procedure 
Male C57Bl/6 mice (6-8 weeks; Charles River, Sulzfeld, Germany) were 
anaesthetized by an intraperitoneal injection of ketamine (100 mg/kg) and xylazine 
(10 mg/kg). Surgical preparation of cremaster muscles and intravital microscopy were 
performed as described previously (80). Inflammatory stimulation was achieved by 
intrascrotal injection of 300 ng of recombinant murine TNF (R&D Systems) diluted 
in 400 µl PBS, 4 h prior to intravital microscopic observation. At the same time, 
flavopiridol (11 ng in 250 µl PBS; bolus sufficient to reach 25 nM plasma 
concentration) was injected intravenously. The control group received intravenous 
administration of PBS (250 µl).  
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3.5.2 Intravital microscopy 
In each animal, at least five single unbranched postcapillary venules with diameters 
of 17.5 to 35 µm were analyzed. During a 15 min observation period, leukocyte 
rolling, adhesion, and transendothelial migration were assessed by near-infrared 
reflected light oblique transillumination microscopy. Videotaped images were 
evaluated off-line using CAPIMAGE software (Zeintl). Leukocyte rolling flux fraction is 
defined as the flux of rolling leukocytes in percent of total leukocyte flux. The total 
number of adherent leukocytes was determined for each venule segment (100 µm) 
and is expressed per 104 µm2 of venule surface area. Emigrated cells were counted 
in an area reaching out 75 µm to each side of a vessel over a distance of 100 µm 
vessel length and are presented per 104 µm2 tissue area. Centerline blood flow 
velocity was measured by using intraarterially administered microspheres (0.96 µm; 
FluoSpheres; Invitrogen). The wall shear rate [s-1] was estimated as 8 x [Vb/d], where 
Vb refers to the mean blood flow velocity and d to the diameter of the vessel. Mean 
blood flow velocity, Vb, was approximated by multiplying the centerline blood flow 
velocity with 0.625 (81). The number of leukocytes in whole blood was determined at 
the end of each experiment using Coulter ACT Counter (Coulter Corp., Miami).  
3.6 Cell adhesion assay 
Confluent HUVECs in 24-well plates were stimulated 30 minutes with flavopiridol 
(100nM) prior to TNF (10 ng/ml) activation for 24 hours. Freshly isolated neutrophils 
(106/ml, 100 µl/well) were coincubated with HUVECs for 30 minutes. The suspension 
was centrifuged for 3 minutes at 800 x g at room temperature. After incubation for 30 
minutes at 37°C, nonadherent cells were removed by washing twice with prewarmed 
PBS+ Ca2+/Mg2+. 
Adhered neutrophils were quantified by a MPO assay. MPO activity was assessed 
photometrically at a wavelength of 450 nm with a substrate solution (see 3.4.4). A 
standard curve of MPO activity with an increasing number of neutrophils has been 
performed in parallel with each assay.  
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3.7 Flow cytometry 
Table 3.1: Antibodies used for flow cytometry. 
 
3.7.1 Determination of cell surface expression of adhesion molecules 
Confluent HUVECs in 24-well plates were treated 30 minutes with increasing 
concentrations of flavopiridol prior to activation with TNF (10 ng/ml) for 6 hours (E-
selectin) or 24 hours (ICAM-1, VCAM-1). Then, cells were washed twice with pre-
warmed PBS, removed by careful trypsinization, and fixed in formaldehyde 4%. After 
one washing step with PBS, cells were centrifuged (1000 rpm, 5 minutes, RT). The 
supernatant was removed and the pellet was incubated with antibodies against 
human ICAM-1, E-selectin, or VCAM-1 for 45 minutes at room temperature. 
Afterwards, cells were analyzed by flow cytometry (FACSCalibur, BD Biosciences, 
Heidelberg, Germany). 
3.7.2 Determination of cell surface expression of CD11b 
Neutrophils (106/ml, 100 µl) were incubated with flavopiridol 30 minutes before 15 
minutes activation with fMLP (10-7 M). Then, cells were fixed with 4% formaldehyde 
and washed with PBS followed by incubation with saturating concentrations of FITC-
labeled antibody against CD11b for 45 minutes at room temperature. Cells were 
washed once with PBS, resuspended in PBS and analyzed by flow cytometry. At 
least 5,000 events were acquired. 
3.7.3 Determination of oxidative stress in neutrophils 
Oxidative stress in neutrophils was assessed by measuring the intracellular oxidation 
of dihydrorhodamine (DHR) to rhodamine. Neutrophils (106/ml, 100 µl) in suspension 
Specificity Format Isotype Dilution Provider 
CD11b FITC Monoclonal antibody 1:20 AbD Serotec 
E-selectin PE Monoclonal antibody 1:20 Tebu-bio 
ICAM-1 FITC Monoclonal antibody 1:25 BIOZOL 
VCAM-1 FITC Monoclonal antibody 1:20 BD Pharmingen 
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were primed with DHR (1 µM) for 10 minutes at 37°C. Cells were pretreated for 30 
minutes with 100 nM flavopiridol and activated with fMLP (10-7 M) for 15 minutes. The 
reaction was stopped on ice and the cells were analyzed by flow cytometry. At least 
5,000 events were acquired. 
3.8 Quantitative RT-PCR 
3.8.1 Isolation of RNA of tissue sections 
Total mRNA from liver tissues from the concanavalin A model was isolated using the 
RNeasy Mini Kit (Qiagen, Hilden, Germany). The tissues, each about 20 mg, were 
homogenized in 300 μl RLT buffer (provided with the RNeasy Mini Kit) using a 
homogenizer. Then, procedures where followed as default by the RNeasy Mini Kit 
protocol. Finally, RNA was eluted with RNase-free water and amounts were 
quantified by measuring the absorption at 260 nm (A260) and 280 nm (A280) 
(NanoDrop, Wilmington, DE, USA). On an agarose gel the intensity ratio of ribosomal 
28S and 18S RNA was used for evaluation of RNA integrity.  
RNA was isolated from RNAlater-stored cremaster muscle tissues using the RNeasy 
Fibrous Tissue Kit (Qiagen, Hilden, Germany). Tissue was homogenized as 
described above for liver tissues and following procedures were performed as 
described by the RNeasy Fibrous Tissue Kit protocol.  
Samples were stored at -85°C until used for reverse transcription. 
3.8.2 Isolation of RNA of HUVECs 
Total RNA was extracted using the RNeasy mini Kit (Qiagen GmbH, Hilden, 
Germany) according to the manufacturer’s instructions. Cells were cultured in 6-well 
plates and were treated as indicated. Thereafter, cells were lysed and homogenized 
in the presence of RLT buffer and procedures where followed as default by the 
RNeasy Mini Kit protocol. The purified RNA was eluted with RNase-free water and 
quantification of the samples was performed using NanoDrop (see 3.8.1). Verification 
of RNA integrity was determined and samples were stored at -85°C until used for 
reverse transcription. 
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3.8.3 Reverse transcription 
Reverse transcription was performed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, DA, USA) according to the 
manufacturer’s manual. Equal amounts of total RNA, 500 ng for liver and cremaster 
muscle tissues or 1500 ng for HUVECs were re-transcribed for 2 hours at 37°C. The 
cDNA was stored at -20° C until used for quantitative RT-PCR. 
3.8.4 Quantitative Real-Time PCR 
All primers and probes were designed using the Primer Express® 2.0 software 
(Applied Biosystems) and were obtained from biomers.net (Ulm, Germany). The 
probe oligonucleotide sequence was labeled with the reporter dye 6-
carboxyfluorescein (FAM) at the 5’ end and the quencher dye tetramethyl-6- 
carboxyrhodamine (TAMRA) at the 3’ end. In Table 3.2 sequences of forward as well 
as reverse primers and probe are displayed. 
 
Table 3.2: Primer and probe sequences. 
 
ICAM-1   
forward mouse 5’-CTG CTG CTT TTG AAC AGA ATG G-3’ 
reverse mouse 5’-TCT GTG ACA GCC AGA GGA AGT G-3’ 
probe mouse 5’-AGA CAG CAT TTA CCC TCA G-3’ 
forward human 5’-GCA GAC AGT GAC CAT CTA CAG CTT-3’ 
reverse human 5’-CTT CTG AGA CCT GTG GCT TCG T-3’ 
probe human 5’-CCG GCG CCC AAC GTG ATT CT-3’ 
 
E-selectin   
forward mouse 5’-CAA CGT CTA GGT TCA AAA CAA TCA G-3’ 
reverse mouse 5’-TTA AGC AGG CAA GAG GAA CCA-3’ 
probe mouse 5’-CAC AAA TGC ATC GTG GGA-3’ 
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GAPDH   
forward mouse 5’-TGC AGT GGC AAA GTG GAG AT-3’ 
reverse mouse 5’-TGC CGT GAG TGG AGT CAT ACT-3’ 
probe mouse 5’-CCA TCA ACG ACC CCT TCA TTG-3’ 
forward human 5’-GGG AAG GTG AAG GTC GGA GT-3’ 
reverse human 5’-TCC ACT TTA CCA GAG TTA AAA GCA G-3’ 
probe human 5’-ACC AGG CGC CCA ATA CGA CCA A-3’ 
 
Quantitative RT-PCR was performed using the AB 7300 RealTime PCR system, 
together with the TaqMan Gene Expression Master Mix (Applied Biosystems) 
according to the manufacturer’s instructions. PCR on GAPDH was used as internal 
reference and serial dilution of cDNA served as standard curves. Fluorescence-
development was analyzed using the AB 7300 system software and calculation of 
relative mRNA content was done according to a mathematical model for relative 
quantification of real time PCR products (82). 
3.9 Immunocytochemistry 
HUVECs were seeded on 8-well ibiTreat μ-slides (ibidi GmbH, Munich, Germany). 
After stimulation, cells were washed once with ice-cold PBS+ Ca2+/Mg2+ and fixed in 
4% formaldehyde for 10-15 minutes. After one PBS washing step, cells were 
permeabilized by 0.2% Triton X-100 in PBS for exactly 2 minutes. Then, cells were 
washed three times for 5 minutes with PBS, unspecific binding was blocked by 
incubation with 0.2% BSA in PBS for 60 minutes. Cells were incubated with the 
primary antibody against p65 (Santa-Cruz Biotechnology Inc., 1:200 in 0.2% 
BSA/PBS) for 60 minutes. After three washes with PBS for 5 minutes, cells were 
incubated with the Alexa Fluor® 488-conjugated secondary antibody (Invitrogen, 
1:400 in 0.2% BSA/PBS) for 60 minutes. Afterwards, cells were washed again three 
times with PBS, and covered with PermaFluor mounting medium (VWR, Darmstadt, 
Germany). Images were obtained with a Zeiss LSM 510 Meta confocal laser 
scanning microscope (Zeiss, Jena, Germany). 
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3.10 Western blot analysis 
Western blot analysis is an extensively used technique to identify specific proteins in 
various protein mixtures, e.g. cell lysates or tissue homogenates. It includes the 
electrophoretic separation of proteins according to their molecular weights, their 
transfer to a membrane (“blotting”), and their visualization by immunodetection.  
3.10.1 Preparation of samples  
HUVECs were treated as indicated and washed twice with ice-cold PBS. The PBS 
was removed completely and cells were lysed by adding RIPA buffer (for non-
phosphorylated proteins) or lysis buffer (to sustain phosphorylated status of proteins) 
followed by freezing at -80°C. Cells were thawed on ice, scratched from the 
plate/dish and transferred to 1.5 ml reaction tubes. Cellular debris was removed by 
centrifugation (14,000 rpm, 10 min, 4°C). Supernatants were transferred to a new 
reaction tube and aliquots were taken for protein quantification using the 
bicinchoninic protein assay (BCA). 
 
RIPA buffer   Lysis buffer  
Tris/HCl 50 mM  Tris/HCl 50 mM 
NaCl 150 mM  NaCl 150 mM 
Nonidet NP 40 1%  Nonidet NP 40 1% 
Deoxycholic acid 0.25%  Deoxycholic acid 0.25% 
SDS 0.10%  SDS 0.10% 
add before use:   add before use:  
Complete® 4.0 mM  Complete® 4.0 mM 
PMSF 1.0 mM  PMSF 1.0 mM 
Na3VO4 1.0 mM  Na3VO4 0.3 mM 
NaF 1.0 mM  NaF 1.0 mM 
H2O ad 100 mL  -Glycerophosphate 3.0 mM 
   Pyrophosphate 10 mM 
   H2O2 600 µM 
   H2O ad 100 mL 
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3.10.2 Protein quantification: bicinchoninic protein assay 
Bicinchoninic protein assay (BCA) was performed as described previously (83). 
Protein samples (10 μl) were incubated with 200 μl BCA reagent for 30 minutes at 
37°C. Absorbance of the complex was measured photometrically at 550 nm. Protein 
standards were obtained by diluting a stock solution of BSA (2 mg/ml). Linear 
regression was used to determine the actual protein concentration of each sample.  
5x SDS-sample buffer was added to the lysates, which were boiled for 5 minutes at 
95°C for inactivation. Protein samples were kept at -20°C until use. 
 
5x SDS-sample buffer  
Tris/HCl 3.125 M, pH 6.8 
Glycerol 10 mL 
SDS 5% 
DTT 2% 
Pyronin Y 0.025% 
H2O ad 20 mL 
 
3.10.3 SDS-PAGE 
Proteins were separated by discontinuous SDS-polyacrylamid gel electrophoresis 
(SDS-PAGE) according to Laemmli (84) using Power Tec™ HC from Bio-Rad 
(Munich, Germany). Prior to loading the samples, the apparatus was assembled as 
described by the producer and the chamber was filled with ice-cold electrophoresis 
buffer. 
Protein concentrations of the probes were unified by adding the required volume of 
1x SDS sample buffer. Then, probes were boiled for 5 minutes at 95°C before 
loading the samples on the SDS gel. Empty slots were filled with an appropriate 
volume of 1x SDS-sample buffer. The molecular weight of proteins was determined 
by loading the Page Ruler™ Prestained Protein Ladder on the gel. 
Electrophoresis was carried out at 100 V for 21 min for protein stacking and 200 V for 
45 min for protein separation. 
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Stacking gel  Separating gel (10%)  
PAA solution 30% 1.275 mL PAA solution 30% 5.0 mL 
1.25 M Tris/HCl, pH 6.8 0.75 mL 1.5 M Tris/HCl, pH 8.8 3.75 mL 
SDS 10% 75 μL SDS 10% 150 μL 
H2O 5.25 mL H2O 6.1 mL 
APS 75 μL APS 75 μL 
TEMED 20 μL TEMED 20μL 
 
Electrophoresis buffer  
Tris base 3.0 g 
Glycine 14.4 g 
SDS 1.0 g 
H2O ad 1.0 L 
3.10.4 Electroblotting 
After separating on the SDS-PAGE, proteins were electrophoretically transferred to a 
nitrocellulose membrane (Hybond ECL™, Amersham Biosciences, NJ, USA) using a 
Trans-Blot® SD Semi-Dry Transfer Cell from Bio-Rad. Prior to blotting, the membrane 
was incubated for at least 30 min in anode buffer on a shaking platform. For semi-dry 
transfer, the gel-membrane sandwich is placed between carbon plate electrodes. 
Therefore, one sheet of thick blotting paper (Whatman, Schleicher & Schüll, Dassel, 
Germany) was soaked with anode buffer and rolled onto the anode. Subsequently, 
the membrane and the gels were added. Finally the stack was covered with another 
sheet of thick blotting paper soaked with cathode buffer. The transfer cell was closed 
and transfer was carried out at 15 V for 1 h. 
 
Anode buffer  Cathode buffer  
Tris 12 mM Tris 12 mM 
CAPS 8 mM CAPS 8 mM 
Methanol 15% SDS 0.1% 
H2O  H2O  
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3.10.5 Protein detection 
Prior to the immunological detection of the relevant proteins, unspecific protein 
binding sites were blocked with PBS containing 5% skimmed milk powder (blotto 5%) 
for 2 hours at room temperature. Afterwards, detection of the proteins was performed 
by incubating the membrane with the respective primary antibody at 4°C overnight. 
After four washing steps with PBS containing 0.1% Tween (PBS-T), the membrane 
was incubated with the secondary antibody, followed by 4 additional washing steps. 
All steps regarding the incubation of the membrane were performed under gentle 
agitation. 
In order to visualize the proteins, two different methods have been used depending 
on the labels of secondary antibodies. 
 
Antibodies directly labeled with infrared (IR) fluorophores 
Secondary antibodies coupled to IRDyeTM 800 and Alexa Fluor® 680 with emission at 
800 and 700 nm, respectively, were used. Membranes were incubated for 2 hours 
with the secondary antibody before three washing steps with PBS-T and one time 
washing with PBS to remove the interfering Tween 20. After washing, membranes 
were scanned and analyzed using the Odyssey infrared imaging system version 2.1. 
After scanning the membrane with two-color detection, bands were quantified using 
Odyssey software. 
 
Antibodies coupled to horseradish peroxidase (HRP) 
Proteins were detected with ECL (enhanced chemiluminescence) when the 
secondary antibody was conjugated to HRP (horseradish peroxidase). Membranes 
were incubated for 2 hours with the secondary antibody prior to four washing steps 
with PBS-T. Then, the membrane was gently agitated in ECL PlusTM Western Blotting 
detection reagent (Amersham Bioscience) for 1 minute protected from light, and 
layered between two plastic sheets afterwards. Chemiluminescence was detected by 
exposing the membranes to an X-ray film for the appropriate time period in a 
darkroom. X-ray films were developed in a table processor (Curix 60 Developing 
System, Agfa-Gevaert AG).  
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Table 3.3: Primary anti 
bodies. 
 
 
Table 3.4: Secondary antibodies. 
3.10.6 Unspecific protein staining of gels and membranes 
To control equal loading of the gel and the performance of the transfer, 
polyacrylamide gels were stained for 10 minutes with Coomassie staining solution. 
Afterwards, gels were extensively washed with destaining solution until proteins 
appeared as blue bands. 
After protein detection, membranes were stained with Ponceau solution for 5 minutes 
and destained with distilled water. 
Antigen Isotype Dilution in Provider 
β-actin mouse monoclonal 1:1,000 blotto 1% Chemicon 
Cdk8 goat polyclonal 1:1,000 blotto 1% Santa Cruz 
Cdk9  mouse monoclonal 1:1,000 blotto 1% Santa Cruz 
IB rabbit polyclonal 1:1,000 blotto 1% Santa Cruz 
IKK/ phospho rabbit polyclonal 1:500 BSA 5% Cell Signaling 
LIMK1 rabbit polyclonal 1:1,000 BSA 5% Cell Signaling 
NF-B p65 rabbit polyclonal 1:500 blotto 1% Santa Cruz 
NF-B p65 
phosphoSer536 
rabbit polyclonal 1:1,000 BSA 5% Cell Signaling 
Antibody Dilution in Provider 
Goat anti-mouse IgG1-HRP 1:1,000 blotto 1% Biozol 
Goat anti-mouse IgG2b-HRP 1:1,000 blotto 1% Southern 
Biotechnology 
Goat anti-rabbit: HRP 1:1,000 blotto 1% Dianova 
Alexa Fluor® 680 goat anti-mouse IgG 1:10,000 blotto 1% Molecular Probes 
Alexa Fluor® 680 goat anti-rabbit IgG 1:10,000 blotto 1% Molecular Probes 
IRDyeTM 800CW goat anti-mouse IgG 1:20,000 blotto 1% LI-COR 
Biosciences 
IRDyeTM 800CW goat anti-rabbit IgG 1:20,000 blotto 1% LI-COR 
Biosciences 
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Coomassie staining solution  Coomassie destaining solution  
Coomassie blue G  0.3%   
Glacial acetic acid 10% Glacial acetic acid 10% 
Ethanol 45% Ethanol 33% 
H2O  H2O  
 
 
 
 
 
 
3.11 Transfer of nucleic acids into HUVECs 
3.11.1 Transfection of siRNA  
For transient transfection with the indicated siRNAs, HUVECs were electroporated 
using the Nucleofector® II device in combination with the HUVEC Nucleofector® Kit 
(both from Lonza Cologne AG, Germany). In order to silence the expression of 
LIMK1 or Cdk8, HUVECs were transiently transfected with On-TARGETplus 
Individual Duplexes (LIMK1 siRNA) or On-TARGETplus SMARTpool (Cdk8 siRNA) 
(Dharmacon, Lafayette, CO, USA). On-Targetplus siCONTROL non-targeting siRNA 
was used as a control. Each siRNA was suspended in Dharmacon 1x siRNA buffer, 
aliquoted and stored at -80°C. The concentration of siRNA was confirmed using a 
NanoDrop (Wilmington, DE, USA).  
 
siRNA Target sequences Provider 
LIMK1 5’-GAGCAUGACCCUCACGAUA-3’ Dharmacon 
 5’-GCCCAGAUGUGAAGAAUUC-3’  
Cdk8 5’-GGACAGAAUAUUCAAUGUA-3’ Dharmacon 
 5’-GAGCAAGGCAUUAUACCAA-3’  
 5’-AGAAAUAGCAUUACUUCGA-3’  
 5’-CGUCAGAACCAAUAUUUCA-3’  
Non-targeting (nt) 5’-UGGUUUACAUGUCGACUAA-3’ Dharmacon 
Ponceau solution  
Ponceau S   0.1% 
Glacial acetic acid 5% 
H2O  
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3.11.2 Experimental procedure  
For each transfection, 2 x 106 HUVECs were suspended in 100 μl HUVEC 
Nucleofector Solution and added to 3 μg of the respective siRNA. The mixture of 
cells and siRNA was transferred to an Amaxa certified cuvette and transfection was 
performed (program A-034). Immediately after electroporation, 950 μl of prewarmed 
growth medium was added to the cells. Afterwards, cells were seeded into 24-well 
plates (250,000 cells per well) and 24 hours after transfection, cells were stimulated 
with TNF for additional 24 hours prepared for flow cytometry analysis. Transfection 
efficiency was checked by Western blot analysis. For this purpose cells were seeded 
in 6-well plates (500,000 cells per well). 
3.11.3 Application of shRNA via adenoviral vectors 
Additionally, we used adenoviral vectors encoding short hairpin RNA (shRNA) for 
gene function analysis. HUVECs, containing shRNA control and shRNA Cdk9 vectors 
were purchased from Sirion (Sirion Biotech GmbH, Martinsried, Germany). These 
cells were seeded into 24-well plates and 72 hours after infection, cells were 
incubated for additional 24 hours with TNF and prepared for FACS analysis. 
Efficient knock-down of Cdk9 was checked by Western blot analysis (cells were 
seeded in 6-well plates). 
3.11.4 Dual Luciferase® Reporter assay system  
Because of their distinct evolutionary origins, firefly and renilla luciferases have 
different enzyme structures and substrate requirements. These differences make it 
possible to selectively discriminate between their respective bioluminescent 
reactions. Thus, using the Dual Luciferase® Reporter (DLR) assay system, the 
luminescence from the firefly luciferase reaction may be quenched while 
simultaneously activating the luminescent reaction of Renilla luciferase. 
The expression plasmid pGL4.32 [luc2P/NF-B-RE/Hygro], a firefly luciferase 
reporter gene, contains five copies of an NF-B response element (NF-B-RE). As 
expression control, pGL4.74 [hRluc/TK], a Renilla luciferase was used (Promega, 
Madison, WI, USA). HUVECs were co-transfected with a ratio of 10:1 of expression 
plasmid and expression control by electroporation using amaxa® HUVEC 
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Nucleofector® kit (Lonza Cologne AG). After transfection, 80,000 cells/ml were 
seeded in 96-well plates and 24 h later stimulated with increasing concentrations of 
flavopiridol (1 to 300 nM) for 30 minutes followed by 5.5 hours TNF-treatment. 
Subsequently, cells were washed once with PBS+ Ca2+/Mg2+, completely removed 
and lysed with 20 μl Passive Lysis Buffer (1x; diluted 1:5 from 5x Passive Lysis 
Buffer, Promega, Mannheim, Germany). Following a freezing step, cell lysates were 
allowed to thaw 15 minutes at room temperature under mild agitation. Luciferase 
Assay reagent II and Stop & Glo buffer were prepared freshly according to the 
manufacturer’s instructions (DLR Assay System, Promega) and used for injectors 1 
and 2, respectively. The luminometer was programmed to perform a 2 sec. 
measurement delay followed by a 10 sec. measurement read for both luciferase 
activities. 20 μl of each sample were transferred into luminometer plates and 
measured using a luminometer (Berthold Orion II, Berthold Detection Systems, 
Pforzheim, Germany). Reaction was initiated by injecting 100 μl of Luciferase Assay 
reagent II followed by Stop & Glo buffer into each well. 
NF-B promoter activity was assessed as x-fold change of firefly luciferase activity 
after normalization for Renilla luciferase activity. 
3.12 Electrophoretic mobility shift assay 
3.12.1 Extraction of nuclear proteins 
For the preparation of nuclei, HUVECs were treated as indicated and washed twice 
with ice-cold PBS. The PBS was removed completely and cells were lysed by adding   
400 μl nuclear extraction buffer A. Cells were scraped off the plate/dish and 
transferred to 1.5 ml reaction tubes. Cells were allowed to swell on ice for 15 min. 
Nonidet P-40 (0.625%) was added, followed by 10 sec. of vigorous vortexing. Probes 
were centrifuged (14,000 rpm, 1 minute, 4°C), supernatants removed, and pellets 
incubated for 30 minutes under agitation at 4°C in 40 μl nuclear extraction buffer B. 
After centrifugation (14,000 rpm, 5 minutes, 4°C), supernatants were collected and 
frozen at -80°C. Protein concentrations were determined by Bradford assay. 
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Extraction buffer A   Extraction buffer B  
HEPES, pH 7.9 10 mM  HEPES, pH 7.9 20 mM 
KCl 10 mM  NaCl 0.4 mM 
EDTA 0.1 mM  EDTA 0.1 mM 
EGTA 0.1 mM  EGTA 0.1 mM 
DTT 1.0 mM  DTT 1.0 mM 
PMSF 0.5 mM  PMSF 0.5 mM 
   Glycerol 25% 
 
3.12.2 Protein quantification: Bradford assay 
Bradford assay (Bradford solution, Bio-Rad) was performed as described previously 
(85). It employs Coomassie Brilliant Blue as a dye, which binds to proteins. 10 μl 
protein samples were incubated with 190 μl Bradford solution (1:5 dilution in water) 
for 5 min. Thereafter, absorbance was measured photometrically at 592 nm (Tecan 
Sunrise Absorbance reader, TECAN). Protein standards were obtained by diluting a 
stock solution of BSA (500 µg/ml). Linear regression was used to determine the 
actual protein concentration of each sample.  
3.12.3 Electrophoretic Mobility Shift Assay 
The oligonucleotide for NF-B with the consensus sequence 5’-AGT TGA GGG GAC 
TTT CCC AGG C-3’ was purchased from Promega. Using the T4 polynucleotide 
kinase the oligonucleotides were 5’ end-labeled with [-32P]-ATP. Equal amounts of 
nuclear protein were incubated with 2 μg poly(dIdC) and 3 μl of freshly prepared 
reaction buffer for 10 minutes at room temperature. The binding-reaction was started 
by adding 1 μl of the radioactive oligonucleotide and carried out for 30 minutes at 
room temperature. The protein-oligonucleotide complexes were separated by gel 
electrophoresis (Power Tec™ HC, BioRad) with 0.25 x TBE buffer at 100 V for 60 
minutes using non-denaturating polyacrylamide gels (5% PAA, 20% glycerol). After 
electrophoresis, gels were exposed to Cyclone Storage Phosphor Screens 
(Canberra-Packard, Schwadorf, Austria) for 24 hours, followed by analysis with a 
phosphor imager station (Cyclone Storage Phosphor System, Canberra-Packard). 
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5x Binding buffer  Loading buffer  
Tris/HCl 50 mM Tris/HCl 250 mM 
NaCl 250 mM Glycerol 40% 
MgCl2 5.0 mM Bromphenolblue 0.2% 
EDTA 2.5 mM   
Glycerol 20%   
 
Reaction buffer  
5x Binding buffer 90% 
Loading buffer 10% 
DTT 2.6 mM 
 
TBE 10x  
Tris 890 mM 
Boric acid 890 mM 
EDTA 20 mM 
H2O  
 
3.13 In vitro IKK kinase activity assay 
The effect of flavopiridol on purified IKK activity was determined using the HTScan® 
IKK Kinase Assay Kit according to the instructions of the manufacturer (Cell 
Signaling Technology, Frankfurt/M., Germany). This assay measures the effect of 
flavopiridol on the phosphorylation of a biotinylated IB- (Ser-32) substrate peptide. 
A phospho-IB- (Ser-32/36)-specific mouse monoclonal antibody was used to 
detect the phosphorylated substrate peptide. For assay standardization, the kit 
provides an active GST-IKK kinase fusion protein. Purified IKK kinase was 
pretreated with different concentrations of flavopiridol (1-300 nM) 5 minutes prior to 
the treatment of substrate peptide. Each kinase assay was performed in duplicate. 
IKK activity was expressed relative to kinase buffer 1x. 100µM Staurosporine was 
used as positive control.  
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3.14 Kinome array (PepChip) 
A kinome array (PepChip) was performed to study the effects of flavopiridol on 
overall signaling in endothelial cells. PepChip performance and analysis of the results 
were done as described previously (86, 87) in collaboration with Dr. Jos Joore from 
Pepscan System BV, Lelystad, The Netherlands. Confluent HUVECs in 4x 100 mm 
dishes were treated with TNF for 15 minutes or 30 minutes with 100 nM flavopiridol 
prior to 15 minutes TNF incubation. After two washing steps with ice-cold PBS, 
native protein lysates of these cells were generated by lysing cells with M-PER 
Mammalian Protein Extraction Reagent (Pierce, Rockford, IL), containing 2.5 mM 
sodium pyrophosphate, 2 mM sodium -glycerophosphate, 1 mM Na3VO4, and 1 mM 
NaF. Lysates were centrifuged at 14,000 rpm for 10 minutes at 4°C, and 
supernatants were frozen immediately in liquid nitrogen. Afterwards, 70 µl 
lysates/array was mixed with 10 µl activation solution (20 µCi [-33P] ATP, 50% 
glycerol, 5 mM DTT, 50 mM MgCl2, 50 mM MnCl2, 250 µg/ml PEG 8000, and 250 
µg/ml BSA) and centrifuged 5 minutes at 14,000 g. Next, 70 µl of the supernatant 
was loaded onto the array and incubated for 2 hours at 37°C in saturated humidity. 
On the PepChip, 1152 different peptides with specific phosphorylation motifs for the 
respective kinases were spotted in triplicates. Chips were washed in 2 cycles, first 5 
minutes in 2 M NaCl containing 1% Triton X-100, followed by 5 minutes in PBS 
containing 1% Triton X-100. Afterward, chips were rinsed 3 times with distilled water 
and then air-dried. 
Phosphor-storage screens were exposed to the chip for 24 hours to determine and to 
quantify the phosphorylation status of peptides (i.e., kinase substrates), which gave 
information about the activity of the associated upstream kinase. The phosphorylation 
status of the chips was compared spot by spot. The results were ranked by extent of 
inhibition of phosphorylation.  
3.15 Protein Kinase Assay (33PanQinase® Activity Assay) 
A radiometric protein kinase assay (33PanQinase® Activity Assay) was used for 
measuring the kinase activity of 255 protein kinases. The analysis was done in 
collaboration with Dr. Frank Totzke from ProQinase GmbH, Freiburg, Germany.  
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All kinase assays were performed in 96-well FlashPlatesTM from Perkin Elmer 
(Boston) in a 50 μl reaction volume. The reaction cocktail was pipetted in 4 steps in 
the following order: 10 μl of non-radioactive ATP solution (in H2O), 25 μl of assay 
buffer/[-33P]-ATP mixture, 5 μl of test sample in 10% DMSO, 10 μl of 
enzyme/substrate mixture. Flavopiridol was tested at 9 final semi-log assay 
concentrations in the range from 1 x 10-05 M to 1 x 10-09 M with a final DMSO 
concentration of 1%. The assay for all enzymes contained 60 mM HEPES-NaOH, pH 
7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na3VO4, 1.2 mM DTT, 50 μg/ml PEG20000,     
1 μM ATP/[-33P]-ATP (approx. 6 x 1005 cpm per well), protein kinase, and substrate.  
Since 9 distinct concentrations of flavopiridol were tested against each kinase, the 
evaluation of the raw data resulted in 9 values for residual activities per kinase. 
Based on each 9 corresponding residual activities, IC50 values were calculated using 
Prism 5.02 for Windows (GraphPad; www.graphpad.com). 
3.16 Statistical Analysis 
Statistical analysis was performed with Prism software (version 3.03; GraphPad 
Software, San Diego, CA). All experiments were performed at least three times 
unless otherwise indicated in the figure legend.  
Data were expressed as mean value ± SEM, and analyzed using One Way ANOVA, 
Student’s t-test, or Mann-Whitney rank sum test. P values < 0.05 were considered as 
statistically significant. 
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4 Results 
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4.1 Anti-inflammatory effects of flavopiridol in vivo 
4.1.1 Concanavalin A-induced liver injury model 
The concanavalin A-induced liver injury model was performed in collaboration with 
PD Dr. Gabrielle Sass and Prof. Dr. Gisa Tiegs from the Division of Experimental 
Immunology and Hepatology, University Medical Center Hamburg-Eppendorf, 
Hamburg. 
4.1.1.1 Flavopiridol protects against concanavalin A-induced liver injury  
Concanavalin A (ConA) in a dosis of 15 mg/kg bodyweight is widely used as the 
optimal dose to induce murine hepatitis (88). We pretreated the mice with flavopiridol 
before intravenous administration of a single dose of ConA (15 mg/kg bodyweight). 
After eight hours we determined plasma transaminase activities as a pathologically 
important marker for liver injury. When the mice were pretreated with flavopiridol, 
ConA-induced hepatitis was greatly suppressed, as proven by a large decrease in 
the levels of the transaminases ALT and AST (7621 ± 690 U/L vs. 4245 ± 1403 U/L 
of ALT; 9156 ± 742 U/L vs. 3570 ± 952 U/L of AST) (Figure 4.1).  
 
A    B 
 
Figure 4.1: Flavopiridol protects against ConA-induced liver injury.  
Mice were either treated (i.v.) with flavopiridol (FP, 44 ng in 250 µl PBS, n = 6) or vehicle (250 µl PBS, 
n = 6) 15 minutes prior to ConA injection (15 mg/kg bodyweight). Liver tissues were removed eight 
hours after ConA administration and plasma transaminase levels of ALT (A) and AST (B) were 
assessed. *, p < 0.01 vs. ConA, t-test. 
 
*
*
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4.1.1.2 Liver necrosis is reduced by flavopiridol 
Liver damage was analyzed histologically eight hours after injection of ConA. Liver 
tissue was removed and embedded in paraffin for H&E staining. We observed 
degenerative changes and necrosis in the histological sections of livers from mice 
after eight hours of ConA treatment. Mice pretreated with flavopiridol presented 
decreased liver necrosis resulting in less hepatocyte destruction as shown in Figure 
4.2 A. For statistical analysis the liver parenchyma with necrotic injury were 
calculated (Figure 4.2 B). 
 
A 
 
B 
 
Figure 4.2: Liver necrosis is reduced by flavopiridol. 
(A) Representative H&E-stained sections of livers after eight hours ConA treatment with or without 
pretreatment of flavopiridol (FP, 44 ng in 250 µl PBS). Original magnification, 200x. Bar, 50 µm. 
Arrows indicate necrotic area. (B) The graph represents the quantitative evaluation of liver 
parenchyma with necrotic injury. HPF (high power field) = original magnification, 200x. 
  
ConA FP + ConA
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4.1.1.3 Flavopiridol inhibits the infiltration of neutrophils into the liver 
Neutrophils are the key initiators of lymphocyte recruitment and liver injury caused by 
ConA (89). Liver tissue sections were stained for neutrophil naphthol esterase to 
specify the phenotype of emigrated leukocytes. The number of infiltrated neutrophils 
in the liver parenchyma was counted around hepatic and portal venules and 
sinusoids in stained sections. Pretreatment with 100 nM flavopiridol attenuated the 
ConA-induced transmigration of neutrophils (Figure 4.3 A). In addition, we 
investigated the myeloperoxidase (MPO) activity of the liver, an index of neutrophil 
infiltration. Pretreatment with flavopiridol significantly suppressed ConA-induced MPO 
activity and, therefore, neutrophil infiltration into liver tissue (Figure 4.3 B).  
 
A 
 
B 
 
 
Figure 4.3: Flavopiridol attenuates the infiltration of neutrophils into the liver tissue. 
(A) Representative sections of liver tissue demonstrate staining for naphthol AS-D chloroacetate 
esterase. Arrows indicate extravasated neutrophils. Original magnification, 400x. Bar, 100µm. (B) For 
statistical evaluation of the infiltrated neutrophils MPO activity of liver tissues was measured.  
*, p < 0.01 vs. ConA, t-test. 
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4.1.1.4 Flavopiridol reduces levels of ICAM-1 and E-selectin in the liver 
Upon ConA injection, a massive induction of hepatic ICAM-1 and E-selectin 
expression occurs (90). We performed quantitative RT-PCR analysis of liver tissues 
to assess ICAM-1 and E-selectin mRNA levels. In ConA-induced liver injury samples, 
we discovered reduced ICAM-1 mRNA levels when mice were pretreated with 
flavopiridol. In addition, we also found that mRNA levels of the endothelium-specific 
cell adhesion molecule E-selectin were suppressed with flavopiridol. These results 
suggest that flavopiridol might also have an impact on liver endothelial cells. 
 
A    B 
 
Figure 4.4: Flavopiridol reduces ConA-induced ICAM-1 and E-selectin mRNA levels. 
Quantitative RT-PCR analysis of ConA-treated liver tissue. Flavopiridol-pretreated liver tissues 
showed reduced ICAM-1 (A) and E-selectin mRNA (B) levels. ICAM-1 and E-selectin expression in 
ConA-treated mice was set as 1.0, respectively. Data are expressed as ratios ICAM-1/GAPDH and E-
selectin/GAPDH.  
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4.1.2 Cremaster muscle model 
The surgical preparation of the cremaster muscle and intravital microscopy were 
performed in collaboration with Dr. Alexander Khandoga and Prof. Dr. Fritz 
Krombach from the Walter Brendel Center of Experimental Medicine, University of 
Munich. 
4.1.2.1 Flavopiridol reduces leukocyte-endothelium interactions in vivo 
We studied leukocyte adhesion and transmigration in TNF-treated cremaster 
muscle venules using intravital microscopy (IVM). Flavopiridol was administered 
intravenously before the mice were treated intrascrotally with TNF for four hours 
prepared for microscopical analysis. Leukocyte adherence on the venular 
endothelium was reduced by almost 40%, when mice were treated with flavopiridol 
(8.7  1.4 n/104 µm2 vs. 12.4  1.8 n/104 µm2) (Figure 4.5 A). The number of 
extravasated leukocytes was significantly reduced in mice co-treated with flavopiridol 
in comparison to mice treated with TNF alone (11.2  0.5 n/104 µm2 vs. 17.5  0.6 
n/104 µm2) (Figure 4.5 B).  
 
A    B 
 
Figure 4.5: Flavopiridol attenuates TNF-evoked leukocyte-endothelium interaction in vivo. 
Mice were treated (i.v.) with flavopiridol (FP, 11 ng in 250 µl PBS, n=3) or PBS as control (n=3) 
followed by intrascrotal injection of TNF (TNF, 300 ng in 400 µl PBS). The number of adherent (A) 
and transmigrated (B) leukocytes was quantified in cremasteric venules by intravital microscopy four 
hours after TNF-injection. *, p < 0.05 vs. TNF, Mann-Whitney rank sum test. 
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4.1.2.2 Microvascular parameters in cremaster muscle venules  
Microvascular parameters during the IVM experiments were measured to assure 
intergroup comparability. Flavopiridol treatment in TNF activated cremaster muscle 
venules did not affect parameters like diameters of analyzed microvessels, centerline 
blood flow velocity, wall shear rate, and systemic white blood counts (Table 4.1). 
 
Table 4.1: Microvascular parameters in cremaster muscle venules. 
Mice were treated (i.v.) with flavopiridol (11 ng in 250 µl PBS, n=3) or PBS as control (n=3) followed by 
intrascrotal injection of TNF (300 ng in 400 µl PBS). In each animal, at least five single unbranched 
postcapillary venules were analyzed. 
 
  
Parameter PBS + TNF Flavopiridol + TNF 
vessel diameter 
(μm) 
26.2 ± 1.1 25.5 ± 0.2 
white blood cell count 
(106 cells/m) 
6.9 ± 1.8 5.8 ± 1.0 
centerline blood flow velocity 
(mm/s) 
1.56 ± 0.04 1.52 ± 0.09 
wall shear rate 
(s-1) 
480.5 ± 30.0 482.9 ± 23.1 
rolling flux fraction 
(%) 
7.9 ± 2.2 8.2 ± 3.1 
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4.1.2.3 Motility of interstitially migrating leukocytes 
We assessed the motility of interstitially migrating leukocytes to further characterize 
the observed effect of leukocyte-endothelium interactions. No differences were 
determined between the two groups in the distribution of rolling velocities, i.e., curve-
line, and straight-line migration distances (Table 4.2), suggesting that flavopiridol has 
no influence on the migration of leukocytes.  
 
 
Table 4.2: Effect of flavopiridol on motility of interstitially migrating leukocytes in vivo. 
Mice were treated (i.v.) with flavopiridol (11 ng in 250 µl PBS, n=3) or PBS as control (n=3) followed by 
intrascrotal injection of TNF (300 ng in 400 µl PBS). For single cell tracking of migrated leukocytes, 
intravital microscopic video recordings were analyzed using the imaging software “Simple PCI” 
(Hamamatsu Corporation/Compix Inc.). On each side of the analyzed vessel, at least 15 emigrated 
leukocytes were identified within ROIs and tracked in the perivascular space within a time period of 5 
min. Parameters of leukocyte motility, such as curve-line and straight-line velocities were automatically 
calculated by the software. 
 
 
Parameter PBS + TNF Flavopiridol + TNF 
Curve-line velocity 
(μm/sec) 
19.3 ± 1.8 20.5 ± 1.4 
Curve-line distance 
(μm) 
96.5 ± 6.5 102.3 ± 5.5 
Straight-line velocity 
(μm/sec) 
3.0 ± 0.7 2.9 ± 0.4 
Straight-line distance 
(μm) 
14.9 ± 2.9 14.6 ± 1.9 
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4.1.2.4 Flavopiridol inhibits ICAM-1 expression in cremaster muscle tissue 
We analyzed the mRNA expression of ICAM-1 to investigate whether flavopiridol has 
an influence on the cell adhesion molecules of the activated endothelium of the 
cremaster muscle. We observed a significant decrease of ICAM-1 mRNA expression 
in flavopiridol treated cremaster muscle tissue (Figure 4.6). 
 
Figure 4.6: Flavopiridol reduces TNF-evoked ICAM-1 mRNA levels in vivo. 
Quantitative RT-PCR analysis of cremaster muscle tissue. ICAM-1 mRNA levels are significantly 
reduced in tissues when mice were treated with flavopiridol (FP; 11 ng in 250 µl PBS, n=3) before 
treatment for four hours with TNF (300 ng in 400 µl PBS). ICAM-1 expression in cremaster muscle 
tissue of TNF-treated mice was set as 1.0. Data are expressed as the ratio ICAM-1/GAPDH.  
*, p < 0.05 vs. TNF, t-test. 
 
  
*
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4.2 Cell viability and apoptosis 
To analyze the influence of flavopiridol on inflammatory actions on endothelial cells in 
vitro we firstly excluded the possibility of a cytotoxic effect of flavopiridol on HUVECs. 
Therefore, we measured the cell viability and apoptotic cell rate up to 48 hours with a 
focus on the concentration of 100 nM which is used in our experiments. 
4.2.1 Effects of flavopiridol on endothelial cell viability 
Confluent HUVECs were stimulated with increasing concentrations of flavopiridol for 
24 and 48 hours. The cells showed a significant reduction of metabolic activity at a 
concentration of 200 nM flavopiridol, although about 80% of the cells remained 
viable. As shown in Figure 4.7, no significant loss of metabolic activity was measured 
by treatment with 100 nM flavopiridol up to 48 hours, indicating no acute cytotoxicity 
of 100 nM flavopiridol compared to the controls (100%). We verified that the 
concentration of flavopiridol used in this study (100 nM) is well-tolerated by HUVECs. 
 
Figure 4.7: Effects of flavopiridol on the viability of HUVECs. 
Confluent HUVECs were treated for 24 and 48 hours with increasing concentrations of flavopiridol (FP, 
10-200 nM). The viable cell rate was determined by CellTiter-Blue
TM 
assay which is based on the 
conversion of resazurin to resorufin as an indicator of the metabolic activity. Viable cell rate is 
expressed as percentage of the control cells (100%). *, p < 0.01 vs. control cells, one way ANOVA. 
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4.2.2 Effects of flavopiridol on apoptosis 
In various types of cancer cells, flavopiridol was shown to induce apoptosis (64). By 
staining the chromatin of endothelial cells with the intercalating agent propidium 
iodide (PI), we determined DNA fragmentation to exclude apoptotic effects of 
flavopiridol. HUVECs were treated with flavopiridol (10-200 nM), stained with 
propidium iodide after 24 and 48 hours, and sub-G0/G1 peaks, adopted widely as 
one of the reliable biochemical markers of apoptosis, were subsequently assessed by 
flow cytometry. We found that flavopiridol has no significant effect on apoptosis in 
confluent HUVECs after 24 and 48 hours (Figure 4.8).  
 
Figure 4.8: Flavopiridol has no influence on apoptosis in endothelial cells. 
Confluent HUVECs were treated 24 and 48 hours with increasing concentrations of flavopiridol (FP,  
10–200 nM) compared with control cells (-). The apoptotic cell rate was analyzed according to the 
Nicoletti method by flow cytometry. Sub-G1 peaks are expressed as apoptotic cell rate as percentage. 
p > 0.05 vs. control cells, one way ANOVA. 
 
In summary, we proofed that 100nM flavopiridol does not induce apoptosis or affect 
viability of confluent HUVECs up to 48 hours. 
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4.3 Anti-inflammatory actions of flavopiridol in vitro 
Flavopiridol demonstrated strong inhibitory effects on inflammatory actions in vivo. 
Thus, to elucidate anti-inflammatory effects of flavopiridol in vitro we analyzed its 
influence on the leukocyte-endothelium interactions and characterized the impact of 
flavopiridol to interfere with inflammation-induced events.  
4.3.1 Flavopiridol reduces neutrophil-endothelium interactions 
The adhesion of human neutrophils to human umbilical vein endothelium cell 
(HUVEC) monolayers was studied in a static adhesion assay in vitro. Neutrophils 
were activated with fMLP (10-7 M) for 30 minutes before they were added to the 
HUVEC monolayer. We investigated neutrophil adhesion to TNF-activated HUVECs 
(24 hours), which were pretreated by flavopiridol (30 minutes). Pretreatment of the 
endothelium with flavopiridol inhibited the adhesion of neutrophils to the TNF-
activated monolayer by 40% (Figure 4.9). When neutrophils were stimulated 30 
minutes with flavopiridol before activation with fMLP, the number of adherent 
neutrophils was not altered, suggesting that the primary target of flavopiridol are 
endothelial cells, but not neutrophils. 
 
 
Figure 4.9: Flavopiridol reduces adhesion of neutrophils to HUVEC monolayers. 
HUVECs were activated 24 hours by TNF with or without pretreatment of flavopiridol (FP, 100 nM). 
Two groups of neutrophils were prepared: one group without treatment and one group with flavopiridol 
(FP, 100 nM) treatment. The numbers of adherent neutrophils on the TNF-activated HUVEC 
monolayer were quantified by analyzing MPO activity. Data are expressed as percentage of TNF-
activated cells. *, p < 0.05 compared to TNF-activated HUVECs, coincubated with neutrophils, t-test; 
#, p < 0.05 compared to TNF-activated HUVECs, coincubated with flavopiridol-treated neutrophils, t-
test. Representative data out of three independent experiments are shown. 
+ FP-treated neutrophils
* #
+ neutrophils
Results  59 
 
4.3.2 Influence of flavopiridol on leukocyte activation  
To further exclude that flavopiridol exerts its anti-inflammatory effects via directly 
targeting neutrophils, the influence of flavopiridol specifically on neutrophils was 
studied. Therefore, we addressed on the activation marker CD11b and oxidative 
burst activity.  
Neutrophils activated for 15 minutes with fMLP (10-7 M) showed a distinct increase of 
CD11b expression compared with untreated neutrophils. Pretreatment of activated 
neutrophils with flavopiridol reduced CD11b expression on the neutrophil surface. We 
found that even with a 10-fold higher concentration of flavopiridol (1 µM) than that 
used in our experiments (100 nM) the inhibitory effect on the expression of CD11b 
was not further affected (Figure 4.10 A). This indicates that flavopiridol has an effect 
on this cell surface marker, which is not expansible with increasing concentrations. 
Further investigations about the interactions between flavopiridol and neutrophils are 
necessary to make a concluding statement. 
Polyphenols are known to act as scavenger of reactive oxygen species (ROS) 
released during the respiratory burst of neutrophils. Human neutrophils were 
stimulated with fMLP (10-7 M) and production of ROS [resulting in dihydrorhodamine 
(DHR) oxidation] was assessed in the presence or absence of 100 nM and 1 µM 
flavopiridol. We observed no influence of flavopiridol on the ROS synthesis in 
neutrophils (Figure 4.10 B), which also indicates that the polyphenol flavopiridol does 
not simply act as a ROS scavenger. Due to these results we in the following focused 
on the action of flavopiridol on endothelial cells. 
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Figure 4.10: Effect of flavopiridol on leukocyte activation. 
(A) Quantitative evaluation of the expression of the adhesion molecule CD11b. Expression of CD11b 
markedly increased after 15 minutes fMLP (10
-7
 M) stimulation compared with the control group (Co). 
Preincubation with flavopiridol attenuated the increase of expression of CD11b. Flavopiridol at a 
concentration of 100 nM and 1 µM act comparably. *, p < 0.05 vs. fMLP, one way ANOVA, n = 3. 
(B) Isolated neutrophils were loaded with DHR and activated by fMLP (10
-7
 M) for 30 minutes. Some 
neutrophils were also treated with flavopiridol (100 nM and 1 µM) 30 minutes before activating by 
fMLP. ROS production of neutrophils was assessed by measuring the intracellular oxidation of DHR in 
a flow cytometer. n.s., not significant vs. fMLP, one way ANOVA, n = 3. 
 
4.3.3 Flavopiridol reduces the expression of cell adhesion molecules 
Activation of endothelial cells is characterized by expression of cell surface-adhesion 
molecules (CAM), such as the intercellular-adhesion molecule (ICAM-1), the vascular 
cell-adhesion molecule (VCAM-1), and E-selectin. Exposure of cells to TNF (10 
ng/ml) induced a strong up-regulation of ICAM-1, VCAM-1, or E-selectin surface 
expression (Figure 4.11 A) as detected by flow cytometry. Pretreatment with 
flavopiridol (10-200 nM) for 30 minutes inhibited the TNF-induced upregulation of 
ICAM-1 (IC50 = 27 nM), VCAM-1 (IC50 = 74 nM), and E-selectin (IC50 = 118 nM) in a 
clear concentration-dependent manner. To figure out whether flavopiridol effects 
transcriptional regulation, we performed quantitative RT-PCR analysis to determine 
the mRNA levels of ICAM-1. As shown in Figure 4.11 B, TNF induced a strong 
increase of ICAM-1 mRNA that is attenuated up to 70% by pretreatment with 100 nM 
flavopiridol. Flavopiridol alone did not affect the basal ICAM-1 mRNA expression. 
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Figure 4.11: Flavopiridol reduces the expression of cell adhesion molecules on HUVECs. 
(A) HUVECs were either left untreated (Co, control cells) or treated with TNF (TNF, 10 ng/ml) for 24 
hours (ICAM-1 and VCAM-1) or six hours (E-selectin). Additionally, cells were preincubated with 
increasing concentrations of flavopiridol (FP, 10–200 nM) for 30 minutes prior to TNF. ICAM-1, 
VCAM-1, and E-selectin expression on the cell surface of HUVECs were assessed by flow cytometry. 
Data are expressed as x-fold increase of TNF activation. *, p < 0.001 vs. TNF, one way ANOVA,    
n = 3. (B) HUVECs were treated with flavopiridol (FP, 100 nM) alone for four hours or 30 minutes 
preincubation of flavopiridol were followed by four hours TNF (10 ng/ml) activation. ICAM-1 mRNA 
expression was analyzed by quantitative RT-PCR. Data are expressed as ratio of ICAM-1/GAPDH and 
TNF-stimulation (four hours) was set as 1.0. *, p < 0.001 vs. TNF, t-test, n = 3. 
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4.4 Effects of flavopiridol on NF-B signaling 
4.4.1 Flavopiridol reduces NF-B promoter activity 
Flavopiridol has the potency to reduce TNF-induced expression of classical NF-B-
dependent genes in HUVECs, including the adhesion molecules E-selectin, ICAM-1, 
and VCAM-1 (Figure 4.11). The promoters of the genes coding for these CAMs 
contain consensus binding sites for the transcription factor NF-B (91). To analyze 
whether the inhibition was due to reduced transcriptional activation by NF-B we 
used a luciferase-based in vitro NF-B reporter gene assay. In fact, flavopiridol 
suppressed TNF-induced NF-B-dependent gene expression dose-dependently 
(Figure 4.12).  
 
Figure 4.12: Flavopiridol reduces NF-B promoter activity. 
HUVECs were cotransfected with a firefly luciferase reporter vector, containing NF-B binding sites 
and a renilla luciferase reporter vector as control. 24 hours after transfection, HUVECs were 
preincubated with increasing concentrations of flavopiridol (1-300 nM) 30 minutes before activation by 
TNF for 5.5 hours. A Dual Luciferase
®
 Reporter assay system was used to assess NF-B promoter 
activities, which are expressed as ratio firefly luciferase/renilla luciferase activities. NF-B promoter 
activity of TNF-stimulated cells was set as 1.0. *, p < 0.05 vs. TNF, one way ANOVA, n = 3. 
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4.4.2 Flavopiridol has no effect on IKK/ and IB  
We were now interested to investigate which stage of the NF-B activation cascade 
is affected by flavopiridol. TNF activates NF-B via the canonical pathway based on 
phosphorylation-induced, proteasome-mediated degradation of IB. The key 
regulatory step in this pathway involves the activation of a high molecular weight IB 
kinase (IKK) complex. In a cell-free kinase activity assay we observed no effect of 
flavopiridol on recombinant human IKK kinase (Figure 4.13 A). 
We also investigated the influence of flavopiridol on the activation (phosphorylation) 
of IKK/ in HUVECs. After 5 minutes treatment with TNF, phospho-IKK/ was 
upregulated, which was not altered by flavopiridol pretreatment (Figure 4.13 B).  
 
A 
 
B 
 
Figure 4.13: Flavopiridol has no influence on IKK/. 
(A) Influence of increasing concentrations of flavopiridol on IKK kinase activity was measured by 
optical density (HTScan
®
 IKK kinase assay). IKK activity was expressed relative to kinase buffer 1x 
(Co, control), 100 µM Staurosporine (St) was used as positive control. *, p < 0.05 vs. control, one way 
ANOVA, n = 3. (B) Western blot analysis was performed to investigate the influence of pretreatment 
with flavopiridol (FP, 100 nM) in TNF-activated HUVECs on phospho-IKK/. The cells were 
pretreated 30 minutes with the protein phosphatase inhibitor calyculin (100 nM). -actin was used as a 
loading control. Representative data out of three independent experiments are shown. 
 
  
flavopiridol  (nM)
*
- - + - + - + FP 
- 5 5 15 15 30 30 TNF (min)
-actin
p-IKK/
64 Results   
 
For its activation, NF-B has to be released from IB, which is achieved by 
phosphorylation of IB on two serine residues (Ser32/Ser36) followed by 
proteasomal degradation. As Western blot data show in Figure 4.14, TNF induced a 
rapid degradation of IB within minutes, followed by its reappearance after 60 
minutes. Pre-treatment with flavopiridol resulted in no difference of TNF-mediated 
IB degradation. Additionally, we analyzed IB at later time points (120–360 min), 
discovering a better recovering of IB in flavopiridol-pretreated HUVECs.  
 
 
Figure 4.14: Flavopiridol has no influence on degradation of IB. 
Western blot analysis was performed to investigate the influence of pretreatment with flavopiridol (FP, 
100 nM) in TNF-activated HUVECs on the degradation of IB. -actin was used as a loading 
control.  
4.4.3 Flavopiridol has no influence on p65 
We tested whether flavopiridol has an effect on the nuclear translocation of p65. In 
the absence of TNF, p65 is localized in the cytoplasm and treatment with TNF 
increases nuclear translocation of p65 (Figure 4.15 A). Translocation of p65 was not 
altered when the cells were pretreated with flavopiridol. IKK is known to 
phosphorylate p65 at Ser 536 and phospho-p65 (Ser536) is associated with an 
increased nuclear translocation of NF-B. Thus, we investigated whether flavopiridol 
influences the phosphorylation of p65 at Ser536 in TNF-activated HUVECs. As 
shown in Figure 4.15 B, flavopiridol has no effect on TNF-induced phosphorylation 
of p65 at Ser536.  
In isolated nuclear extracts, incubated with [32P]-labeled NF-B oligonucleotides, 
flavopiridol does not inhibit TNF-induced binding activity of NF-B to DNA (Figure 
4.15 C). 
These findings suggest that flavopiridol has no influence on TNF-mediated p65 
translocation, phosphorylation, and NF-B DNA-binding activity, although we have 
shown that flavopiridol inhibits NF-B-dependent gene expression. 
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Figure 4.15: Flavopiridol has no influence on TNF-induced phosphorylation and translocation 
of p65 as well as on NF-B DNA-binding. 
(A) Immunofluorescence staining to visualize that 30 minutes pretreatment of flavopiridol (FP, 100 nM) 
has no effect on the nuclear translocation of the p65 subunit of NF-B in TNF-activated HUVECs. 
Bar, 50 µm. (B) Western blot analysis to investigate the influence of 30 minutes pretreatment of 
flavopiridol (FP, 100 nM) on phospho-p65 (Ser536) in TNF-activated HUVECs. -actin was used as a 
loading control. (C) NF-B binding activity was determined in nuclear extracts by electromobility shift 
assay (EMSA). HUVECs were treated with TNF for the indicated time points with or without 30 
minutes pretreatment of flavopiridol (FP, 100 nM). Representative data out of three independent 
experiments are shown. 
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4.5 Analysis of kinome alterations by flavopiridol  
Because almost all cellular biochemical pathways are under strict control of 
reversible phosphorylation by kinases, we assumed that the anti-inflammatory effects 
of flavopiridol would be reflected in altered activity of these kinases. A major interest 
was to clarify the molecular mechanisms of the known kinase inhibitor flavopiridol in 
inflammatory events. Therefore, we performed a global approach using a kinome 
array (PepChip) containing 1,176 different oligopeptide kinase substrates. 
The kinome array compared the phosphorylation patterns of HUVECs treated with 
TNF for 15 minutes or treated 30 minutes with 100 nM flavopiridol prior to 15 
minutes TNF incubation. The effects of flavopiridol on rapid signal transduction 
were examined. Table 4.3 provides the top affected kinases with the highest 
reduction of activity. Strikingly, an important decrease in LIMK1, JNK1, CK2, and 
PKCθ was seen.  
 
Table 4.3: Rapid flavopiridol-induced changes of kinome profiles in TNF-treated HUVECs. 
Kinome array (PepChip) data show kinases reduced most in their activity (R.A., residual activity) in 
lysates prepared from TNF-activated HUVECs pretreated with flavopiridol (100 nM) compared with 
TNF-activated HUVECs. 
 
Kinase Peptide sequence R.A. 
PKCθ ESRSGSNRRER 0.61 
CK2  QVSSLSESEES 0.46 
JNK APAAPTPAAPA 0.31 
LIMK1 MASGVTVNDE 0.10 
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4.5.1 The influence of LIMK1, JNK, CK2 and PKC on ICAM-1 expression 
As a next step we investigated whether the inhibition of these kinases is linked to the 
effect of flavopiridol on ICAM-1 expression to hit on the underlying mechanisms of 
the anti-inflammatory effects of flavopiridol in HUVECs. TNF-activated HUVECs 
lacking LIMK1 show no change in ICAM-1 expression compared with nt siRNA 
transfected HUVECs (Figure 4.16).  
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Figure 4.16: Effect of LIMK1 on ICAM-1 protein levels. 
(A) Untransfected HUVECs and HUVECs transfected with LIMK1 siRNA and non-targeting (nt) siRNA 
were co-incubated with TNF for 24 h. ICAM-1 expression was assessed by flow cytometry, 
expressed as x-fold increase of TNF-activation.  
(B) Immunoblotting visualizes sufficient downregulation of LIMK1, -actin was used as a loading 
control. 
 
We used specific inhibitors of JNK, CK2, and PKCθ to determine the role of these 
kinases in the regulation of adhesion molecules induced by TNF. We tested 
whether treatment with the JNK inhibitor SP600125, the CK2 inhibitors TBB and 
quinalizarin (Q1), or the myristoylated PKCθ pseudosubstrate inhibitor (PKCθ inh.) 
affected the expression of ICAM-1 induced by TNF. The JNK inhibitor SP600125 
only slightly decreased the expression of ICAM-1 by 20% at a concentration of 20 
µM. The CK2 inhibitors and the PKCθ pseudosubstrate inhibitor had no impact on the 
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Co nt siRNA LIMK1 siRNA
LIMK1
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TNF-induced ICAM-1 expression (Figure 4.17 A, B, C). These data suggest that the 
effects of flavopiridol on ICAM-1 levels are not caused by LIMK1, JNK, CK2, or 
PKCθ.  
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Figure 4.17: Effect of JNK, CK2, and PKCθ inhibitors on ICAM-1 protein levels. 
TNF-activated HUVECs were pretreated with increasing concentrations of the JNK inhibitor 
SP600125 (0.1-20 µM) (A), the CK2 inhibitors TBB (1-10 µM) and quinalizarin (Q1, 10-30 µM) (B), and 
the myristoylated PKCθ pseudosubstrate inhibitor (PKCθ inh., 0.1-10 µM) (C). ICAM-1 expressions 
were assessed by flow cytometry and expressed as x-fold increase of the TNF activation. *, p < 0.05 
vs. TNF, one way ANOVA, n = 3. 
*
SP600125 (µM) 
+ TNF
TBB (µM)   Q1 (µM)  
+ TNF
PKC inh. (µM) 
+ TNF
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4.6 Involvement of Cdks in inflammatory events 
4.6.1 IC50 profiling of flavopiridol  
Since the kinome array did not cover Cdks, we determined the IC50 profile using 255 
protein kinases (33PanQinase® Activity Assay). Flavopiridol appears as an unspecific 
kinase inhibitor (6), however this IC50 profiling reveals that flavopiridol in low 
concentrations primarily acts as a Cdk inhibitor. The effects of flavopiridol on Cdks 
are shown in Table 4.4. We were especially interested in activities of flavopiridol at 
low nanomolar concentrations to gain information about the responsible actions for 
the strong inhibition of TNF induced ICAM-1 levels (IC50 = 27 nM). Only a few Cdks 
were sensitive to flavopiridol in the 1–100 nM range: Cdk4, Cdk6, Cdk8, and Cdk9.  
 
Table 4.4: IC50 profiling of flavopiridol (
33
PanQinase
®
 Activity Assay). 
The IC50 profile of flavopiridol was determined using 255 protein kinases, the table provides the IC50 
values of flavopiridol on Cdks. 
 
 
  
Kinase IC50 (nM) Kinase IC50 (nM) 
Cdk1/CycA 120 Cdk4/CycD3 19 
Cdk1/CycB1 110 Cdk5/p25NCK 480 
Cdk1/CycE 96 Cdk5/p35NCK 570 
Cdk2/CycA 210 Cdk6/CycD1 36 
Cdk2/CycE 260 Cdk7/CycH 440 
Cdk3/CycE 280 Cdk8/CycC 21 
Cdk4/CycD1 20 Cdk9/CycT 4.9 
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4.6.2 Effect of a specific Cdk4/6 inhibitor on ICAM-1  
The investigation of the effect of Cdk4 and Cdk6 on ICAM-1-expression with the 
specific Cdk4/6 inhibitor fascaplysin seemed interesting because of the kinase 
profiling of flavopiridol (Table 4.4). Our data reveal that fascaplysin has no influence 
on the upregulation of ICAM-1 by TNF in HUVECs (Figure 4.18). Thus, we found no 
correlation between Cdk4/6 and the adhesion molecule ICAM-1. 
 
Figure 4.18: Effect of fascaplysin on ICAM-1 cell surface expression. 
ICAM-1 expressions of HUVECS treated 30 minutes with the dual Cdk4/6-inhibitor fascaplysin (30-
1000 nM) followed by 24 hours treatment of TNF were assessed by flow cytometry. Data are 
expressed as x-fold increase of TNF activation, n = 3. 
 
  
fascaplysin (nM) + TNF
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4.6.3 ICAM-1 expression in the absence of Cdk8 
Another interesting Cdk emerging from the kinase profiling of flavopiridol is Cdk8 
(Table 4.4). TNF-activated HUVECs deficient in Cdk8 show a strong increase in 
ICAM-1 expression compared with nt siRNA transfected HUVECs (Figure 4.19).  
 
A 
 
B 
 
Figure 4.19: ICAM-1 cell surface expression in the absence of Cdk8. 
(A) HUVECs transfected with Cdk8 siRNA and non-targeting (nt) siRNA were co-incubated with TNF 
for 24 hours. ICAM-1 expressions were assessed by flow cytometry, expressed as x-fold increase of 
the control cells, respectively. *, p < 0.05 vs. nt siRNA transfected HUVECs treated with TNF, t-test. 
(B) Immunoblotting visualizes efficient downregulation of Cdk8, -actin was used as a loading control. 
Representative data out of three independent experiments are shown. 
 
  
- + - + TNF
nt siRNA Cdk8 siRNA
*
- + Cdk8 siRNA
Cdk8
-actin
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4.6.4 The loss of Cdk9 has a strong effect on ICAM-1 expression 
To study the functional significance of Cdk9 in the regulation of ICAM-1 in vitro, we 
used a shRNA-based strategy to knock down Cdk9 expression. The continuous 
expression of the Cdk9 shRNA from the adenovirus in the transduced cells has the 
advantage of a stable knock-down of Cdk9 over a longer period of time. The protein 
levels of Cdk9 were significantly reduced by the Cdk9 shRNA (Figure 4.20 A). We 
discovered that TNF-activated HUVECs transduced with shRNA Cdk9 show a 
strong reduction of ICAM-1 protein levels compared with cells expressing Cdk9 
(Figure 4.20 B). For the Cdk9 shRNA-transduced HUVECs, ICAM-1 expression was 
reduced by 70% compared with cells infected with the control shRNA. These results 
strongly suggest that the inhibition of Cdk9 has an impact on TNF-dependent 
upregulation of ICAM-1 protein levels in endothelial cells. Cdk9 might represent the 
target of flavopiridol responsible for ICAM-1 reduction. 
 
A 
 
B 
 
Figure 4.20: The loss of Cdk9 has a strong effect on ICAM-1 cell surface expression. 
(A) Detection of Cdk9 in HUVECs transfected with shRNA against Cdk9 (shRNA Cdk9) or a control 
shRNA (shRNA Co) treated with TNF 72 hours after transduction (+) and 24 hours later (++). -actin 
was used as a loading control. (B) 72 hours after transduction the cells were treated 24 hours with 
TNF. ICAM-1 expression is assessed by flow cytometry, expressed as x-fold increase of the control 
cells. *, p < 0.01 vs. shRNA control transduced HUVECs treated with TNF, t-test. Representative 
data out of three independent experiments are shown. 
+ - ++ - shRNA Co
- + - ++ shRNA Cdk9 
Cdk9
-actin
shRNA Co shRNA Cdk9
- + - + TNF
*
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5 Discussion 
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5.1 Flavopiridol protects against inflammatory actions 
Treatment of inflammatory diseases today is largely based on interrupting the 
synthesis or action of mediators that drive the host’s response to injury, such as non-
steroidal anti-inflammatory drugs (NSAIDs), steroids, and antihistamines (92). 
Currently, limited efficacy and severe side-effects of anti-inflammatory agents have 
encouraged the extensive search for more specific compounds for the inflammatory 
response (3). Recently, Cdk inhibitors were suggested to play relevant roles in 
processes regarding immune response. The Cdk inhibitor roscovitine has been 
shown to promote apoptosis of human neutrophils and enhance the resolution of 
inflammation (8). The discovery of flavopiridol in inflammatory responses is still in 
early stages and the key factors and molecular mechanisms that regulate 
inflammatory gene expression are explored insufficiently. 
5.1.1 The impact of flavopiridol on concanavalin A induced liver injury 
Acute liver failure induced by intravenous injection of concanavalin A (ConA) is one 
of the well-known mouse models of T cell-dependent liver injury. This model is 
characterized by inflammatory infiltration of the liver by neutrophils and simultaneous 
increase in levels of transaminases in the blood shortly (8–24 h) after ConA 
challenge (88). The plasma transaminases are important pathological markers and 
elevated levels are associated with liver cell damage (93). Flavopiridol is effective in 
attenuating levels of plasma transaminases ALT and AST, which displays its potency 
in ConA-induced liver injury. Furthermore, flavopiridol protects against a significant 
increase of infiltrated neutrophils after ConA administration, which is an important 
effect since neutrophils are the key initiators of lymphocyte recruitment and liver 
injury caused by ConA (89).  
We used flavopiridol at 100 nM and in clinical studies in several tumor types, 
concentrations between 300 and 500 nM flavopiridol were achieved safely. Phase I/II 
trials with infusional flavopiridol in combination with standard chemotherapy identified 
the maximum tolerated doses using flavopiridol daily for 5, 3, and 1 consecutive days 
with 37.5, 50, and 62.5 mg/m2 per day. Plasma flavopiridol concentrations achieved 
were in the range 1.5–3.5 µM (94). 
TNF has been clearly identified as central mediator of T cell activation-induced 
acute liver failure. TNF directly mediates hepatocellular death but also induces the 
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expression of inflammatory proteins, such as cytokines and adhesion molecules. 
Hence, ConA injection results in a massive induction of ICAM-1, VCAM-1, and E-
selectin in the liver (95). E-selectin is activated by cytokines and initiates neutrophil 
recruitment in sepsis-induced lung injury (96). We found decreased levels of the cell 
adhesion molecules ICAM-1 and E-selectin, which may explain the underlying 
mechanisms for the protective effect of flavopiridol on the ConA-induced liver injury. 
5.1.2 Flavopiridol reduces leukocyte-endothelium interactions in vivo 
For the first time flavopiridol is used in a model of activated cremaster muscle 
venules, which admits the direct intravital observation of the microcirculation in the 
cremaster muscle and therefore adhesion and transmigration of leukocytes on the 
endothelium (97). Leukocytes are recruited locally at the site of inflammation in a 
series of adhesive steps before transendothelial migration through the interstitial 
tissue (22). TNF represents one of the archetypal pro-inflammatory cytokines which 
is rapidly released upon tissue injury or infection (98). We could show that flavopiridol 
reduces adherence and transmigration of leukocytes on/through the TNF-activated 
endothelium in vivo.  
The participation of ICAM-1 is relevant for leukocyte crawling in vivo (99) and 
leukocyte crawling is reported as a distinct postarrest step during leukocyte 
recruitment affecting almost all adherent leukocytes on activated venular endothelium 
(100). Flavopiridol has a strong influence on the endothelium because of the 
significant reduction of the ICAM-1 mRNA levels and the leukocyte-endothelium 
interactions involved. 
5.1.3 Flavopiridol reduces leukocyte-endothelium interactions in vitro 
Studies on flavopiridol in nuclear run-on assays revealed, that 10, 30, and 100 nM 
have very little effect on global cellular transcription. A totally different result was 
obtained when cells were treated with 300 nM flavopiridol. Total transcription was 
dramatically inhibited (64). In vitro, we used in our experiments low dosed flavopiridol 
at 100 nM which is well tolerated by endothelial cells as proven by DNA 
fragmentation and metabolic activity of the HUVECs. Low dosed flavopiridol allows 
us to exclude severe effects on cell viability or global transcription. 
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Neutrophil recruitment at sites of infection or tissue injury is tightly regulated by 
coordinated expression of adhesion molecules on both neutrophils (e.g. CD11b) and 
endothelial cells (e.g. ICAM-1, VCAM-1, and E-selectin) and production of 
cytokines/chemokines (17).  
On endothelial cells, flavopiridol reduces in a concentration dependent manner the 
TNF-induced upregulation of ICAM-1, VCAM-1, and E-selectin cell surface 
expression. This result is in accordance with the reduction of adhesion of neutrophils 
on a TNF-activated HUVEC monolayer. The impact of flavopiridol on transcriptional 
regulation of ICAM-1 strongly suggests that flavopiridol interferes already with the 
transcriptional control of inflammatory proteins. 
Although we did not find an effect with flavopiridol on the white blood cell count and 
the motility of interstitially migrating leukocytes in the cremaster muscle model, in 
vitro flavopiridol has an impact on the CD11b expression. However, the influence of 
flavopiridol on the CD11b expression on the cell surface of neutrophils is not 
concentration-dependent. These results suggest that the impact of flavopiridol on 
leukocytes is not the decisive step in the leukocyte-endothelium interactions 
discovered in vivo and in vitro. The inflammatory response encompasses both the 
production of cytokines and proinflammatory oxidants produced by neutrophils and 
macrophages. The production of these reactive oxygen species (ROS) is 
accompanied by a transient increase in oxygen consumption by the cells, called the 
respiratory burst (101). Polyphenol substances are known to act as potent 
antioxidants (102). The basic structure of flavopiridol is a polyphenol, therefore we 
studied the effect of flavopiridol on ROS production. Examination of respiratory burst 
activity of neutrophils revealed that flavopiridol does not simply act as a ROS 
scavenger.  
Further studies on the underlying mechanisms of flavopiridol-mediated effects on 
neutrophils might be interesting to establish a concluding statement about the 
function of flavopiridol on neutrophils. 
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5.2 The underlying mechanisms of the anti-inflammatory 
properties of flavopiridol 
Previous studies with flavopiridol primarily addressed its effects on diseases linked to 
several hematologic and solid cancers, like chronic lymphocytic leukemia (103). 
Furthermore a function on the HIV Tat protein was reported, thus proposing a 
possible role for flavopiridol in anti-HIV-1 therapy (104). 
Hitherto, the association of flavopiridol with inflammatory processes was suggested in 
two in vivo models: flavopiridol is effective in 
1) treatment of collagen-induced arthritis in mice with suppression of synovial 
hyperplasia and joint destruction (10) and  
2) suppression of hepatic acute phase response proteins by disruption of IL-6 
signaling in hepatocarcinoma cells (11).  
However, the anti-inflammatory mechanisms of action remain unknown. 
We showed that treatment with low-dosed flavopiridol decreased cytokine-induced 
expression of adhesion molecules on protein and mRNA levels at primary endothelial 
cells, which allowed us to investigate the actions of flavopiridol on endothelial cells in 
detail. To get insights into the mechanisms causing the anti-inflammatory effects of 
flavopiridol, we analyzed the underlying molecular pathways of TNF-induced ICAM-
1 regulation. 
5.2.1 Flavopiridol has no effect on the NF-B activation cascade 
Besides its extensive role in regulating the immune response, NF-B signaling is 
critical for the development of various diseases, especially inflammatory diseases 
and tumors. Thus, the NF-B signaling pathway is in the focus for research on 
pharmacological interventions and numerous therapeutic agents that inhibit either 
activation or function of NF-B (105, 106).  
For our work, NF-B attracted attention because it is a key regulator of inflammatory 
responses and NF-B sites in the ICAM-1 promoter play an important role in its gene 
expression (107, 108). 
Interestingly, Takada and Aggarwal have shown that flavopiridol suppressed TNF-
induced activation of NF-B in a dose and time-dependent manner in several cancer 
cell lines (Jurkats, A293, HL60), with optimum inhibition occurring upon treatment of 
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cells with 100 nM flavopiridol for eight hours. The inhibition of NF-B activity was 
linked to suppression of IKK/ activation, inhibition of IB degradation, blocking of 
p65 phosphorylation, p65 nuclear translocation, and NF-B-dependent reporter gene 
transcription. Subsequently, they suggested, that flavopiridol inhibited the activation 
of the proinflammatory transcription factor NF-B and NF-B-regulated gene 
expression which could direct flavopiridol to suppress inflammation (12). 
 
However, in endothelial cells short-time preincubation of 100 nM flavopiridol 
decreased TNF-induced NF-B promoter activity, but had no influence on NF-B 
activation. In HUVECs, TNF-activated phosphorylation of IKK/ is not diminished 
by flavopiridol, as well as phosphorylation and therefore activation of IB. Activation 
of p65 occurs at several phosphorylation sites, PKAc and MSK1 are known to 
phosphorylate Ser276, whereas CK2 and IKK/ phosphorylate Ser529 and Ser536, 
respectively (39, 109). Moreover, flavopiridol has no influence on the TNF-activated 
phosphorylation sites Ser276 and Ser529 (data not shown) as well as Ser536. 
After gaining access to the nucleus, NF-B must be actively regulated to execute its 
fundamental function as a transcription factor. Recent studies have highlighted the 
importance of nuclear signaling in the regulation of NF-κB transcriptional activity 
(105). We could demonstrate that flavopiridol does not affect DNA-binding activity of 
NF-B, verified by electro mobility shift assay (EMSA). The EMSA confirms that 
flavopiridol does not affect the presence of NF-B in the nucleus, although a 
conclusion about transcriptional regulation is not possible, which shows that these 
data are not inconsistent with the elucidated inhibition of NF-B reporter gene 
expression. 
Nevertheless, these data suggest, that the anti-inflammatory effects of flavopiridol in 
HUVECs are not caused via inhibition of NF-B activation. 
5.2.2 Flavopiridol affects LIMK1, CK2, JNK, and PKC 
We performed a global approach via PepChip with flavopiridol-treated HUVECs to 
gain more insights on the effects of flavopiridol on cellular signaling.  
PepChip kinome array is a research tool to investigate the impact of a compound on 
overall kinase activities in the cellular context using cell lysates. The PepChip array 
offers proof of both the direct and indirect actions of the respective compound on 
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kinase activities involved in signal transduction pathways and kinase substrate-
dependent interactions (110). This array was supposed to reveal influences of 
flavopiridol on signaling pathways with relevance to inflammation and to identify a 
mechanism of action of flavopiridol. 
Analyzing kinome profiles of HUVECs treated with flavopiridol identified several 
involved kinases and revealed four kinases, which are reduced most in their activity: 
LIMK1, CK2, JNK, and PKC.  
5.2.3 LIMK1, CK2, JNK, and PKC do not influence inflammatory actions 
One strategy in the search for anti-inflammatory agents is the analysis of the 
suppression of individual inflammatory genes or gene products, or specific subsets of 
genes. In the development of anti-inflammatory drugs little progress has been made 
toward the goal of modulating the transcription of specific subsets of proinflammatory 
genes (111). For our work, a major interest was to investigate the interaction of 
flavopiridol and selective regulation of inflammatory events, in particular the 
regulation of inducible proinflammatory genes. To figure out whether the kinases, 
LIMK1, CK2, JNK, and PKC revealed by PepChip data, are involved in inflammatory 
actions, we investigated their effect on the proinflammatory gene ICAM-1. 
 
An important kinase promoting microtubule stability and actin polymerization in 
human endothelial cells is LIMK1 (112). Genetic deletion of LIMK1 decreased 
neutrophil infiltration in mouse lungs and was efficacious to decrease ocular 
inflammation (113, 114). We tested the role of LIMK1 in the regulation of ICAM-1 
expression and found that LIMK1 is not involved in inflammatory processes related to 
ICAM-1.  
 
CK2 is supposed to play an important role in the regulation of expression of genes 
implicated in inflammation through the control of NF-B (115). Already Singh and 
Ramji (2008) deliberated whether CK2 could be an important regulator of the 
inflammatory response (115). The specific CK2 inhibitors, TBB and quinalizarin, have 
no influence on TNF-upregulated ICAM-1 expression in HUVECs. Although the data 
of the PepChip suggest a link between CK2 and flavopiridol we also did not identify 
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an influence of flavopiridol on the CK2 dependent phosphorylation site Ser529 of NF-
B (data not shown). 
 
Inflammatory cytokines have been shown to stimulate adhesion molecule expression 
in endothelial cells, in part, by stimulating c-Jun N-terminal kinase (JNK) (116). On 
HUVECs, the JNK inhibitor SP600125 is approved to exclude unspecific kinase 
effects at a concentration of 10µM (117). By applying SP600125 at a concentration of 
10µM we discovered no effect on the TNF-induced ICAM-1 upregulation. 
 
Activation of the PKC/NF-B signaling pathway was found to play a major role in the 
transcriptional induction of the ICAM-1 gene (28). In particular PKC plays a key role 
in T cell activation, proliferation and cytokine production as well as specific activation 
of AP-1 and NF-B (118). No data exists about the function of PKC in inflammatory 
events in endothelial cells. With a PKC-selective inhibitor, we found that PKC did 
not alter the TNF-induced ICAM-1 levels. 
5.3 Cdks in inflammation-induced processes 
Cdks were initially identified as key components of the cell cycle machinery, but 
subsequently they have been shown to play roles in cell differentiation, transcription, 
and inflammation (119). Recent reviews present strong links between cancer and 
inflammation and that Cdk inhibition plays a key role due to accelerated inflammatory 
resolution by promoting apoptosis. Currently, the role of Cdks in the resolution of 
inflammation are unclear but a number of studies have been launched (8). 
Interestingly, an IC50 profiling revealed flavopiridol in low concentrations primarily as 
a Cdk inhibitor. It is noteworthy that concentrations of 100 nM flavopiridol were not 
sufficient for inhibitory effects on kinases like CK2, IKK, JNK1, or PKCθ. To gain 
information about the responsible actions for the strong inhibition of TNF-induced 
ICAM-1 levels (IC50 = 27 nM), we were interested in activities of flavopiridol at low 
nanomolar concentrations. Only a few Cdks were sensitive to flavopiridol in the        
1-100 nM range: Cdk4, Cdk6, Cdk8, and Cdk9.  
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5.3.1 Cdk4 and 6 in inflammation-induced processes 
A study evaluated how systemic administration of flavopiridol and a Cdk4/6 selective 
inhibitor exerted an antiarthritic effect by suppressing proliferation of synovial 
fibroblasts in collagen-induced arthritis in mice. The results argue that flavopiridol 
exerted its effects primarily by Cdk4/6 inhibition (10). By using fascaplysin, a Cdk4/6 
inhibitor, we have shown for the first time that Cdk4 and 6 are not involved in 
affecting ICAM-1 levels activated by TNF. Although reports exist, which predict 
Cdk4 and 6 to be involved in inflammatory adhesion and cytokine production (120, 
121) our data do not support the validation of these assumptions in endothelial cells.  
5.3.2 Cdk8 in inflammation-induced processes 
Another interesting Cdk emerging from the kinase profiling of flavopiridol is Cdk8, 
which has been characterized mostly as a transcriptional repressor (122). In 
comparison with other Cdks little data are known about Cdk8. Recently, Cdk8 was 
demonstrated to be a positive regulator of AP-1 and early growth response family of 
oncogenic transcription factors (123). No data exist concerning a link between Cdk8 
and inflammation. 
We investigated TNF-activated HUVECs deficient in Cdk8 for ICAM-1 expression. 
The finding of an increase of ICAM-1 expression in HUVECs, in the absence of Cdk8, 
excludes Cdk8 as a potential target in anti-inflammatory processes. Cdk8 and its 
activator cyclin C are components of the RNAPII holoenzyme, where they function as 
a negative regulator of transcription, resulting in suppression of transcription (124). 
Thus, it is possible that inhibition of Cdk8 might result in abolishment of suppression 
of transcription leading to an increase of ICAM-1 expression.  
5.3.3 The importance of Cdk9 in inflammation 
Already Hou et al (2007) concluded that inhibition of Cdk9 could be a potential 
therapeutic strategy for inflammatory disease because of the disruption of IL-6 
signaling (11). 
P-TEFb, a heterodimer of Cdk9 and cyclin T1, is widely implicated in the control of 
basal gene expression (125). Especially for the P-TEFb complex, flavopiridol showed 
a strong inhibition in our IC50 profiling with an IC50 value of 4.9 nM. Flavopiridol is the 
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most potent P-TEFb inhibitor currently identified and exhibits about tenfold selectivity 
towards P-TEFb compared to other Cdks (126). Disruption of P-TEFb function by the 
Cdk-inhibitor DRB (5,6-Dichloro-1--D-ribofuranosylbenzimidazole) selectively 
blocked TNF stimulation of IL-8 mRNA production (127). Most but not all RNA Pol II 
transcription is sensitive to P-TEFb inhibitors flavopiridol and DRB (128). HUVECs 
with silenced Cdk9 show strongly decreased ICAM-1 protein and mRNA levels (data 
not shown). Thus, our results show that Cdk9 is necessary for cytokine-dependent 
upregulation of ICAM-1. Therefore, we conclude that the anti-inflammatory effect of 
flavopiridol is primarily achieved by an inhibitory effect on Cdk9. 
Caldwell et al. (2006) reported that dnCdk9 repressed the mannose receptor and 
BMPR2 promoter constructs, but had no effect on the COX-2 promoter in 
macrophages, implying that Cdk9 does not support transcription of all macrophage 
genes (129). Therefore it seems plausible that some genes are much less sensitive 
to pharmacological inhibition of Cdk9 and that the sensitivity may be also cell-type 
specific (130). 
5.3.4 Complexity of gene regulatory network: P-TEFb and NF-B 
What process is responsible for the decreased NF-B promoter activity by 
flavopiridol? 
NF-B activates its downstream target genes by pleiotropic mechanisms (131) and 
interestingly, the complexity of gene regulatory network showed that NF-B activation 
is regulated by Cdks (132). Cdks were found to regulate transcriptional activation by 
NF-B through interactions with the co-activator p300. Nissen and Yamamoto (2000) 
showed that P-TEFb is differentially recruited to two NF-B regulated promoters 
indicating that P-TEFb is not a global co-regulator of NF-B, but appears to be 
recruited to only a subset of RelA/p50 response elements (133). Recently, it was 
discovered that a subset of genes, Gro and IL-8, were absolutely dependent on 
phospho-p65 (Ser276) and Cdk9, but others, IB, were not. These data suggest 
that P-TEFb is involved in the activation of a subset of NF-B-dependent genes 
whose mechanism of activation involves Pol II recruitment (125). Baumli et al. (2008) 
reported that some genes are much less sensitive to pharmacological inhibition of 
Cdk9 and that the sensitivity may be also cell-type specific (130). In agreement with 
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these data we show that the recovering and therefore the transcription of IB is not 
impaired by treatment with low dosed flavopiridol in endothelial cells. 
NF-B is needed to enhance the efficiency of transcription elongation and pre-mRNA 
processing (134). In fact, inducible factors, such as NF-B, promote acetylation of 
histones at lysine residues which are then recognized by the protein Brd4. Brd4 
recruits P-TEFb, which promotes elongation and pre-mRNA processing by its ability 
to phosphorylate the C-terminal domain of RNA polymerase II (135). This assumption 
requires a decrease of functional NF-B in the nucleus which results in less 
acetylation of histones. In our experiments we could show that although the amount 
of translocated NF-B and the NF-B DNA-binding activity is not altered the 
expression of the NF-B-dependent gene, ICAM-1, is decreased, suggesting that 
inhibition of Cdk9 is sufficient to reduce ICAM-1 gene expression. 
5.4 Conclusion 
In conclusion, the results presented here demonstrate that flavopiridol protects 
against inflammation-induced endothelial activation in vivo and in vitro.  
For the first time, we investigated the anti-inflammatory potential of flavopiridol on 
endothelial cells. Flavopiridol inhibits TNF-induced NF-B-dependent gene 
expression, but did not affect the NF-B activation cascade. We found an association 
between Cdk9 and inflammatory events in endothelial cells. Our findings suggest the 
inhibition of Cdk9-dependent gene expression as underlying mechanism for the anti-
inflammatory effects of flavopiridol. 
In conclusion, this study highlights flavopiridol as a novel, promising anti-
inflammatory agent, which might reach clinical relevance for the treatment of 
inflammatory diseases. 
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Previous studies with flavopiridol primarily addressed its effects on diseases linked to 
several hematologic and solid cancers, like chronic lymphocytic leukemia (103). 
Recent reviews present strong links between cancer and inflammation and that Cdk 
inhibition plays a key role in the resolution of inflammation (8, 119).  
Based on these considerations, we hypothesized that flavopiridol could exhibit an 
anti-inflammatory potential. In a ConA-induced liver injury, flavopiridol greatly 
suppressed the attenuated levels of transaminases and strongly reduced the 
infiltration of neutrophils in hepatic tissue. Moreover, ConA injection results in a 
massive induction of ICAM-1 and E-selectin levels in the liver, which were as well 
inhibited by flavopiridol. In a second in vivo model, flavopiridol significantly reduced 
leukocyte adhesion and transmigration in TNF-activated cremaster muscle venules.  
In vitro, we used in our experiments low dosed flavopiridol at 100 nM which is well 
tolerated by endothelial cells and allows us to exclude severe effects on cell viability 
and global transcription.  
In HUVECs, flavopiridol inhibited cytokine-induced upregulation of cell adhesion 
molecules and suppressed NF-B-dependent gene expression. However, flavopiridol 
has no effect on the activation of IB kinase, on the phosphorylation of IB, and on 
the nuclear translocation of p65. Taken together, our studies strongly suggest that 
the anti-inflammatory actions of flavopiridol in endothelial cells are not likely to involve 
the TNF-induced activation cascade of NF-B.  
To gain information about the kinase activities of flavopiridol we performed a kinome 
array (PepChip) and a kinase panel (IC50 profiling). The kinome array revealed a 
possible association between the kinases LIMK1, JNK, CK2, and PKCθ and the 
signaling pathways of flavopiridol. Further investigations showed no correlation 
between these kinases and inflammatory actions, therefore we conclude that the anti-
inflammatory effects of flavopiridol are not caused by LIMK1, JNK, CK2, or PKCθ in 
endothelial cells. The IC50 profiling highlighted flavopiridol in low concentrations 
primarily as a Cdk inhibitor and interestingly we found an association between Cdk9 
and inflammatory events in endothelial cells.  
Therefore we conclude that the anti-inflammatory effect of flavopiridol is primarily 
achieved by inhibitory effects on Cdk9.  
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Figure 6.1: Importance of flavopiridol in inflammatory events in endothelial cells. 
Upon stimulating endothelial cells with TNF, NF-B translocates from the cytoplasm to the nucleus. 
There, it binds to its response elements and recruits P-TEFb (Cdk9-cyclin T). The ability of Cdk9 to 
phosphorylate the C-terminal domain of RNA Pol II stimulates inflammatory gene expression. 
Flavopiridol inhibits cytokine-induced inflammatory gene expression. Investigations of the underlying 
mechanisms revealed that the effects are independent of NF-B activation and other kinases which 
are affected by flavopiridol, but due to a strong inhibition of Cdk9. 
 
 
In summary, we could show for the first time that flavopiridol exerts anti-
inflammatory actions and abrogates inflammatory induced leukocyte-
endothelium interactions in vivo and in vitro. We can highlight flavopiridol as a 
novel, promising anti-inflammatory agent, which might reach clinical relevance 
for the treatment of inflammatory diseases. Furthermore we revealed Cdk9 as a 
target with good prospects in inflammatory events. 
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8.1 Abbreviations 
ANOVA   Analysis of variance between groups 
AP-1   Activator protein 1 
AML  Acute myelogenous leukemia 
APS   Ammonium persulfate 
ATP   Adenosine -5’- triphosphate 
BSA   Bovine serum albumin 
CAK  Cdk-activating kinase 
CAM  Cell adhesion molecule 
CAPS  3-(Cyclohexylamino)-1-propanesulfonic acid 
Cdk  Cyclin dependent kinase 
CKI  Cdk inhibitor  
CLL  Chronic lymphocytic leukemia 
ConA  Concanavalin A 
CTD  C-terminal domain 
DHR  Dihydrorhodamine 
DNA   Deoxyribonucleic acid 
DRB  5,6-Dichloro-1--D-ribofuranosylbenzimidazole 
DTT   Dithiothreitol 
ECGM  Endothelial cell growth medium 
ECL   Enhanced chemiluminescence 
ECM  Extracellular matrix 
ECs  Endothelial cells 
EDTA   Ethylenediaminetetreacetic acid 
EGTA  Ethylene glycol-bis(2-aminoethylether) tetraacetic 
acid 
ELISA   Enzyme-linked immunosorbent assay 
ER   Endoplasmatic reticulum 
FACS   Fluorescence-activated cell sorter 
FCS   Fetal calf serum 
FL   Fluorescence 
FP   Flavopiridol 
FSC  Forward scatter 
GAPDH   Glycerin aldehyde 3 phosphate dehydrogenase 
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GTP/GDP   Guanosine-5’-tri/diphosphate 
h   Hour(s) 
H&E  Hematoxylin and eosin 
HEPES  N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic 
acid) 
HIV-1  Human immune deficiency virus 1 
HRP   Horseradish peroxidase 
HUVEC   Human umbilical vein endothelial cell 
ICAM-1  Intercellular adhesion molecule 1 
i.p.  intraperitoneal 
IVM  Intravital microscopy  
JAM  Junctional adhesion molecule 
kDa   Kilo Dalton 
LFA1  Lymphocyte function-associated antigen 1 
LIMK1  LIM kinase 1 
Mac-1  Macrophage antigen 1 
MAPK   Mitogen-activated protein kinase 
mRNA   Messenger RNA 
NCI   National Cancer Institute 
NF-κB   Nuclear factor-kappa B 
nt   Non-targeting 
p-    Phospho- 
PAA   Polyacrylamide 
PBS   Phosphate buffered saline 
PBS-T  Phosphate buffered saline with Tween 
PCR   Polymerase chain reaction 
PI   Propidium iodide 
PIPES   Piperazine-1,4-bis(2-ethanesulfonic acid) 
PKC   Protein kinase C 
PMN  Polymorphonuclear leukocyte 
PMSF   Phenylmethylsulphonylfluoride 
qRT-PCR   Quantitative real-time polymerase chain reaction 
RIPA   Radio Immuno Precipitation Assay 
RNA  Ribonucleic acid 
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ROS  Reactive oxygen species 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SEM   Standard error of mean 
Ser  Serine 
shRNA  Short hairpin RNA 
siRNA  Small interfering RNA 
T/E   Trypsin/EDTA 
TEMED   N,N, N’ N’ tetramethylethylene diamine  
TNF  Tumor necrosis factor  
Tris  Trishydroxymethylaminomethane  
VCAM-1  Vascular cell-adhesion molecule 1 
VEGF  Vascular Endothelial Growth Factor 
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